Viveve Medical (VIVE) 10-K 17 Mar 22 2021 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2021	Mar. 11, 2022	Jun. 30, 2021
Document Information [Line Items]
Entity Central Index Key	0000879682
Entity Registrant Name	VIVEVE MEDICAL, INC.
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2021
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2021
Document Transition Report	false
Entity File Number	1-11388
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	04-3153858
Entity Address, Address Line One	345 Inverness Drive South Building B, Suite 250
Entity Address, City or Town	Englewood
Entity Address, State or Province	CO
Entity Address, Postal Zip Code	80112
City Area Code	720
Local Phone Number	696-8100
Title of 12(b) Security	Common Stock, par value $0.0001 per share
Trading Symbol	VIVE
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	false
Entity Shell Company	false
Entity Public Float			$ 31,351,000
Entity Common Stock, Shares Outstanding		10,619,846
Auditor Firm ID	207
Auditor Name	BPM LLP
Auditor Location	San Jose, California

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 19,162,000	$ 6,523,000	[1]
Accounts receivable, net of allowance for doubtful accounts of $66 and $124 as of December 31, 2021 and 2020, respectively	549,000	770,000	[1]
Inventory	1,472,000	3,254,000	[1]
Prepaid expenses and other current assets	1,055,000	1,031,000	[1]
Total current assets	22,238,000	11,578,000	[1]
Property and equipment, net	1,554,000	2,759,000	[1]
Investment in limited liability company	577,000	833,000	[1]
Other assets	1,544,000	1,460,000	[1]
Total assets	25,913,000	16,630,000	[1]
Current liabilities:
Accounts payable	1,480,000	881,000	[1]
Accrued liabilities	3,053,000	2,416,000	[1]
Paycheck Protection Program loan, current portion	0	918,000	[1]
Total current liabilities	4,533,000	4,215,000	[1]
Note payable, noncurrent portion	5,124,000	4,518,000	[1]
Paycheck Protection Program loan, noncurrent portion	0	425,000	[1]
Other noncurrent liabilities	1,190,000	498,000	[1]
Total liabilities	10,847,000	9,656,000	[1]
Commitments and contingences (Note 10)
Stockholders’ equity:
Common stock, $0.0001 par value; 75,000,000 shares authorized as of December 31, 2021 and 2020; 10,619,846 and 2,171,316 shares issued and outstanding as of December 31, 2021 and 2020, respectively	1,000	0
Additional paid-in capital	256,918,000	226,800,000	[1]
Accumulated deficit	(241,853,000)	(219,826,000)	[1]
Total stockholders’ equity	15,066,000	6,974,000	[1]
Total liabilities and stockholders’ equity	25,913,000	16,630,000	[1]
Series B Preferred Stock [Member]
Stockholders’ equity:
Convertible preferred stock	0	0
Series C Preferred Stock [Member]
Stockholders’ equity:
Convertible preferred stock	$ 0	$ 0
[1]	The condensed consolidated balance sheet as of December 31, 2020 has been derived from the audited consolidated financial statements as of that date.

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Accounts receivable, allowance for doubtful accounts	$ 66	$ 124	[1]
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	75,000,000	75,000,000
Common stock, shares issued (in shares)	10,619,846	2,171,316
Common stock, shares outstanding (in shares)	10,619,846	2,171,316
Series B Preferred Stock [Member]
Convertible preferred stock, shares authorized (in shares)	10,000,000	10,000,000
Convertible preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Convertible preferred stock, shares issued (in shares)	40,504	35,819
Convertible preferred stock, shares outstanding (in shares)	40,504	35,819
Series C Preferred Stock [Member]
Convertible preferred stock, shares authorized (in shares)	10,000,000	10,000,000
Convertible preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Convertible preferred stock, shares issued (in shares)	0	0
Convertible preferred stock, shares outstanding (in shares)	0	0
[1]	The condensed consolidated balance sheet as of December 31, 2020 has been derived from the audited consolidated financial statements as of that date.

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Revenue	$ 6,426	$ 5,479
Cost of revenue	5,806	5,183
Gross profit	620	296
Operating expenses:
Research and development	9,665	5,125
Selling, general and administrative	12,508	13,666
Total operating expenses	22,173	18,791
Loss from operations	(21,553)	(18,495)
Gain on forgiveness of Paycheck Protection Program loan	1,358	0
Modification of warrants	(373)	(1,838)
Interest expense, net	(1,000)	(910)
Other expense, net	(203)	(289)
Net loss from consolidated companies	(21,771)	(21,532)
Loss from minority interest in limited liability company	(256)	(383)
Comprehensive and net loss	(22,027)	(21,915)
Series B convertible preferred stock dividends	(4,691)	(4,149)
Net loss attributable to common stockholders	$ (26,718)	$ (26,064)
Net loss per share of common stock:
Basic and diluted (in dollars per share)	$ (2.65)	$ (16.56)
Weighted average shares used in computing net loss per common share:
Basic and diluted (in shares)	10,089,722	1,573,528

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	November 2019 Offering [Member]Preferred Stock [Member]Series A Preferred Stock [Member]	November 2019 Offering [Member]Preferred Stock [Member]Series B Preferred Stock [Member]	November 2019 Offering [Member]Preferred Stock [Member]Series C Preferred Stock [Member]	November 2019 Offering [Member]Common Stock [Member]	November 2019 Offering [Member]Additional Paid-in Capital [Member]	November 2019 Offering [Member]Retained Earnings [Member]	November 2019 Offering [Member]	Purchase Agreement with LPC [Member]Preferred Stock [Member]Series A Preferred Stock [Member]	Purchase Agreement with LPC [Member]Preferred Stock [Member]Series B Preferred Stock [Member]	Purchase Agreement with LPC [Member]Preferred Stock [Member]Series C Preferred Stock [Member]	Purchase Agreement with LPC [Member]Common Stock [Member]	Purchase Agreement with LPC [Member]Additional Paid-in Capital [Member]	Purchase Agreement with LPC [Member]Retained Earnings [Member]	Purchase Agreement with LPC [Member]	January 2021 Offering [Member]Preferred Stock [Member]Series A Preferred Stock [Member]	January 2021 Offering [Member]Preferred Stock [Member]Series B Preferred Stock [Member]	January 2021 Offering [Member]Preferred Stock [Member]Series C Preferred Stock [Member]	January 2021 Offering [Member]Common Stock [Member]	January 2021 Offering [Member]Additional Paid-in Capital [Member]	January 2021 Offering [Member]Retained Earnings [Member]	January 2021 Offering [Member]	Conversion of Series A Convertible Preferred Stock into Common Stock [Member]Preferred Stock [Member]Series A Preferred Stock [Member]	Conversion of Series A Convertible Preferred Stock into Common Stock [Member]Preferred Stock [Member]Series B Preferred Stock [Member]	Conversion of Series A Convertible Preferred Stock into Common Stock [Member]Preferred Stock [Member]Series C Preferred Stock [Member]	Conversion of Series A Convertible Preferred Stock into Common Stock [Member]Common Stock [Member]	Conversion of Series A Convertible Preferred Stock into Common Stock [Member]Additional Paid-in Capital [Member]	Conversion of Series A Convertible Preferred Stock into Common Stock [Member]Retained Earnings [Member]	Conversion of Series A Convertible Preferred Stock into Common Stock [Member]	Conversion of Series C Convertible Preferred Stock Into Common Stock [Member]Preferred Stock [Member]Series A Preferred Stock [Member]	Conversion of Series C Convertible Preferred Stock Into Common Stock [Member]Preferred Stock [Member]Series B Preferred Stock [Member]	Conversion of Series C Convertible Preferred Stock Into Common Stock [Member]Preferred Stock [Member]Series C Preferred Stock [Member]	Conversion of Series C Convertible Preferred Stock Into Common Stock [Member]Common Stock [Member]	Conversion of Series C Convertible Preferred Stock Into Common Stock [Member]Additional Paid-in Capital [Member]	Conversion of Series C Convertible Preferred Stock Into Common Stock [Member]Retained Earnings [Member]	Conversion of Series C Convertible Preferred Stock Into Common Stock [Member]	Series A and Series B Warrants [Member]Preferred Stock [Member]Series A Preferred Stock [Member]	Series A and Series B Warrants [Member]Preferred Stock [Member]Series B Preferred Stock [Member]	Series A and Series B Warrants [Member]Preferred Stock [Member]Series C Preferred Stock [Member]	Series A and Series B Warrants [Member]Common Stock [Member]	Series A and Series B Warrants [Member]Additional Paid-in Capital [Member]	Series A and Series B Warrants [Member]Retained Earnings [Member]	Series A and Series B Warrants [Member]	Series A-2 and Series B-2 Warrants [Member]Preferred Stock [Member]Series A Preferred Stock [Member]	Series A-2 and Series B-2 Warrants [Member]Preferred Stock [Member]Series B Preferred Stock [Member]	Series A-2 and Series B-2 Warrants [Member]Preferred Stock [Member]Series C Preferred Stock [Member]	Series A-2 and Series B-2 Warrants [Member]Common Stock [Member]	Series A-2 and Series B-2 Warrants [Member]Additional Paid-in Capital [Member]	Series A-2 and Series B-2 Warrants [Member]Retained Earnings [Member]	Series A-2 and Series B-2 Warrants [Member]	Preferred Stock [Member]Series A Preferred Stock [Member]	Preferred Stock [Member]Series B Preferred Stock [Member]	Preferred Stock [Member]Series C Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Series B Preferred Stock [Member]	Total
Balances (in shares) at Dec. 31, 2019																																																		185,218	31,678	0	707,571
Balances at Dec. 31, 2019																																																		$ 0	$ 0	$ 0	$ 0	$ 214,432	$ (197,911)		$ 16,521
Issuance costs	$ 0	$ 0	$ 0	$ 0	$ (33)	$ 0	$ (33)	$ 0	$ 0	$ 0	$ 0	$ (494)	$ 0	$ (494)
Conversion of convertible preferred stock into common stock (in shares)																						(185,218)	0	0	185,218
Conversion of convertible preferred stock into common stock																						$ 0	$ 0	$ 0	$ 0	$ 0	$ 0	$ 0
Issuance of common shares in connection with common warrant exercises																																				$ 0	$ 0	$ 0	$ 0	$ 7,814	$ 0	$ 7,814	$ 0	$ 0	$ 0	$ 0	$ 593	$ 0	$ 593
Issuance of common shares in connection with common warrant exercises (in shares)																																							1,115,863							93,129											1,209,000
Modification of Series A and B warrants in connection with 2020 Warrant Offering																																																		0	0	0	0	1,838	0		$ 1,838
Issuance of Series A-2 and B-2 warrants in connection with 2020 Warrant Offering																																																		0	0	0	0	1,838	0		1,838
Issuance costs for Series A-2 and B-2 warrants in connection with 2020 Warrant Offering																																																		0	0	0	0	(1,838)	0		(1,838)
Issuance costs for Series A-2 and B-2 warrants in connection with 2020 Warrant Offering																																																		0	0	0	0	1,838	0		1,838
Transaction costs in connection with 2020 Warrant Offering																																																		0	0	0	0	(334)	0		(334)
Transaction costs in connection with 2020 Warrant Offering																																																		0	0	0	0	334	0		334
Issuance of stock (in shares)								0	0	0	52,500
Issuance of stock								$ 0	$ 0	$ 0	$ 0	341	0	341
Series B convertible preferred stock dividends																																																		$ 0	$ 0	$ 0	$ 0	(4,149)	0		(4,149)
Series B convertible preferred stock dividends paid in PIK shares (in shares)																																																		0	4,141	0	0			4,141
Series B convertible preferred stock dividends paid in PIK shares																																																		$ 0	$ 0	$ 0	$ 0	4,141	0		4,141
Stock-based compensation expense																																																		$ 0	$ 0	$ 0	$ 0	2,577	0		2,577
Issuance of common shares from employee stock purchase plan (in shares)																																																		0	0	0	84
Issuance of common shares from employee stock purchase plan																																																		$ 0	$ 0	$ 0	$ 0	0	0		0
Issuance of common shares for vesting of restricted stock award granted to consultant (in shares)																																																		0	0	0	25
Issuance of common shares for vesting of restricted stock award granted to consultant																																																		$ 0	$ 0	$ 0	$ 0	0	0		0
Issuance of restricted common shares in connection with consulting agreement (in shares)																																																		0	0	0	10,995
Issuance of restricted common shares in connection with consulting agreement																																																		$ 0	$ 0	$ 0	$ 0	74	0		74
Reverse stock split - rounding adjustment (in shares)																																																		0	0	0	5,931
Reverse stock split - rounding adjustment																																																		$ 0	$ 0	$ 0	$ 0	0	0		0
Net loss																																																		$ 0	$ 0	$ 0	$ 0	0	(21,915)		(21,915)
Balances (in shares) at Dec. 31, 2020																																																		0	35,819	0	2,171,316
Balances at Dec. 31, 2020																																																		$ 0	$ 0	$ 0	$ 0	226,800	(219,826)		6,974	[1]
Issuance costs								$ 0	$ 0	$ 0	$ 0	(70)	0	(70)
Conversion of convertible preferred stock into common stock (in shares)																													0	0	(2,450,880)	2,450,880
Conversion of convertible preferred stock into common stock																													$ 0	$ 0	$ 0	$ 0	$ 0	$ 0	$ 0
Issuance of common shares in connection with common warrant exercises																																																		$ 0	$ 0	$ 0	$ 0	179	0		$ 179
Issuance of common shares in connection with common warrant exercises (in shares)																																																		0	0	0	52,760				52,760
Modification of Series A and B warrants in connection with 2020 Warrant Offering																																																		$ 0	$ 0	$ 0	$ 0	373	0		$ 373
Issuance of stock (in shares)								0	0	0	250,000				0	0	2,450,880	5,666,760
Issuance of stock								$ 0	$ 0	$ 0	$ 0	$ 704	$ 0	$ 704	$ 0	$ 0	$ 0	$ 1	$ 25,121	$ 0	$ 25,122
Series B convertible preferred stock dividends																																																		$ 0	$ 0	$ 0	$ 0	(4,691)	0		(4,691)
Series B convertible preferred stock dividends paid in PIK shares (in shares)																																																		0	4,685	0	0			4,685
Series B convertible preferred stock dividends paid in PIK shares																																																		$ 0	$ 0	$ 0	$ 0	4,685	0		4,685
Stock-based compensation expense																																																		$ 0	$ 0	$ 0	$ 0	3,779	0		3,779
Issuance of common shares from employee stock purchase plan (in shares)																																																		0	0	0	28,130
Issuance of common shares from employee stock purchase plan																																																		$ 0	$ 0	$ 0	$ 0	38	0		$ 38
Issuance of restricted common shares in connection with consulting agreement (in shares)																																																									0
Net loss																																																		$ 0	$ 0	$ 0	$ 0	0	(22,027)		$ (22,027)
Balances (in shares) at Dec. 31, 2021																																																		0	40,504	0	10,619,846
Balances at Dec. 31, 2021																																																		$ 0	$ 0	$ 0	$ 1	$ 256,918	$ (241,853)		$ 15,066
[1]	The condensed consolidated balance sheet as of December 31, 2020 has been derived from the audited consolidated financial statements as of that date.

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Cash flows from operating activities:
Net loss	$ (22,027,000)	$ (21,915,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Provision for doubtful accounts	125,000	454,000
Depreciation and amortization	1,123,000	1,295,000
Stock-based compensation	3,779,000	2,651,000
Non-cash interest expense	606,000	535,000
Loss from minority interest in limited liability company	256,000	383,000
Loss on disposal of property and equipment	113,000	20,000
Modification of warrants	373,000	1,838,000
Forgiveness of Paycheck Protection Program loan	(1,358,000)	0
Changes in assets and liabilities:
Accounts receivable	96,000	349,000
Inventory	2,207,000	1,360,000
Prepaid expenses and other current assets	(24,000)	151,000
Other noncurrent assets	320,000	461,000
Accounts payable	599,000	(727,000)
Accrued and other liabilities	553,000	(2,422,000)
Other noncurrent liabilities	365,000	331,000
Net cash used in operating activities	(12,878,000)	(15,234,000)
Cash flows from investing activities:
Purchase of property and equipment	(456,000)	(781,000)
Net cash used in investing activities	(456,000)	(781,000)
Cash flows from financing activities:
Proceeds from January 2021 Offering, net of issuance costs	25,122,000	0
Proceeds from exercise of common warrants	179,000	8,407,000
Transaction costs in connection with 2020 Warrant Offering	0	(334,000)
Proceeds from purchase of common shares under Purchase Agreement with LPC	704,000	341,000
Proceeds from Paycheck Protection Program loan	0	1,343,000
Proceeds from issuance of common shares from employee stock purchase plan	38,000	0
Net cash provided by financing activities	25,973,000	9,230,000
Net increase (decrease) in cash and cash equivalents	12,639,000	(6,785,000)
Cash and cash equivalents - beginning of period	6,523,000	13,308,000
Cash and cash equivalents - end of period	19,162,000	6,523,000
Supplemental disclosure:
Cash paid for interest	0	0
Cash paid for income taxes	0	0
Supplemental disclosure of cash flow information as of end of period:
Forgiveness of Paycheck Protection Program loan	1,358,000	0
Issuance of Series B convertible preferred stock in settlement of dividends	4,685,000	4,141,000
Issuance of note payable in settlement of accrued interest	602,000	532,000
Net transfer of equipment between inventory and property and equipment	(425,000)	247,000
Operating cash outflows from operating leases	195,000	303,000
Purchase Agreement with LPC [Member]
Cash flows from financing activities:
Transaction costs	(70,000)	(494,000)
November 2019 Offering [Member]
Cash flows from financing activities:
Transaction costs	$ 0	$ (33,000)

Note 1 - The Company and Basis

Note 1 - The Company and Basis of Presentation	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	1. The Company and Basis of Presentation Viveve Medical, Inc. (“Viveve Medical”, the “Company”, “we”, “our”, or “us”) designs, develops, manufactures and markets a platform medical technology, which we refer to as Cryogen-cooled Monopolar RadioFrequency Effective Shelf Registration Statement On July 2, 2021, 3 I.B.6. 3, 3 one third 12 December 31, 2021, not Reduction of Common Warrant Exercise Price On January 19, 2021, 2 2 2 2 no In February March 2021, 40,000 January 2021 On May 4, 2021, 2 2 no As of December 31, 2021, 2 2 2021 On January 19, 2021, “January 2021 The offering comprised of: ( 1 one one one fifth 2 one one one fifth A total of 2,450,880 shares of Series C convertible preferred stock were issued in the January 2021 January 2021, Warrants to purchase a total of 8,117,640 shares of common stock were issued in the January 2021 February March 2021, January 2021 December 31, 2021, January 2021 Series C Convertible Preferred Stock In connection with the closing of the January 2021 With certain exceptions, as described in the Series C Certificate of Designation, the shares of Series C convertible preferred stock have no Each share of Series C convertible preferred stock is convertible at any time at the holder’s option into one All Series C convertible preferred stock have been converted into common stock and there are no remaining shares outstanding. Elimination of Series A Convertible Preferred Stock On December 16, 2020, November 25, 2019. 547,345 Purchase Agreement with Lincoln Park Capital, LLC The Company previously entered into a purchase agreement on June 8, 2020 ( The Purchase Agreement limited the Company’s sale of shares of common stock to LPC to 301,762 shares of common stock, representing 19.99% of the shares of the common stock outstanding on the date of the Purchase Agreement unless (i) shareholder approval was obtained to issue more than such amount or (ii) the average price of all applicable sales of common stock to LPC under the Purchase Agreement equaled or exceeded $6.46 per share. On June 9, 2020, On March 31, 2021, On May 4, 2021, On June 23, 2021, As of December 31, 2021, 2020 On April 15, 2020, April 16, 2020, 2 2 five April 20, 2020. 2020 12 2 2 December 31, 2021, 2 2 Liquidity and Management Plans The Company has adopted the Financial Accounting Standards Board’s (“FASB”) Accounting Standard Codification (“ASC”) Topic 205 40, one The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. However, since inception, the Company has sustained significant operating losses and such losses are expected to continue for the foreseeable future. As of December 31, 2021, December 31, 2021, January 2021 December 31, 2021. December 31, 2021 not March 31, 2023, one To fund further operations, the Company will need to raise additional capital. The Company may no not no

Note 2 - Summary of Significant

Note 2 - Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Significant Accounting Policies [Text Block]	2. Summary of Significant Accounting Policies Financial Statement Presentation The consolidated financial statements include the accounts of the Company and our wholly-owned subsidiaries, Viveve, Inc. and Viveve BV. All significant intercompany accounts and transactions have been eliminated in consolidation. Reclassification of Prior Year Presentation Certain prior year amounts have been reclassified for consistency with the current period presentation. These reclassifications had no December 31, 2020 Reverse Stock Split - December 2020 The Company effected a 1 December 1, 2020. ten one As a result of the reverse stock split, proportionate adjustments were made to the per share exercise price and/or the number of shares issuable upon the exercise or vesting of all then outstanding stock options, deferred restricted stock awards and warrants, which will result in a proportional decrease in the number of shares of the Company’s common stock reserved for issuance upon exercise or vesting of such stock options, deferred restricted stock awards and warrants, and, in the case of stock options and warrants, a proportional increase in the exercise price of all such stock options and warrants. In addition, the number of shares reserved for issuance under the Company’s equity compensation plans immediately prior to the effective date will be reduced proportionately. No fractional shares were issued as a result of the reverse stock split. Stockholders of record who would otherwise have been entitled to receive a fractional share were rounded up to the nearest whole number. The Company issued 5,931 shares of common stock as a result of this rounding adjustment. All of the share numbers, share prices, and exercise prices have been adjusted, on a retroactive basis, to reflect this 1 10 Use of Estimates The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenue, and expenses and the related disclosure of contingent assets and liabilities. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not may Cash and Cash Equivalents The Company considers all highly liquid investments purchased with an original maturity of three one may, Concentration of Credit Risk and Other Risks and Uncertainties To achieve profitable operations, the Company must successfully develop, manufacture, and market its products. There can be no Most of the Company’s products to date require clearance or approvals from the U.S. Food and Drug Administration (“FDA”) or other international regulatory agencies prior to commencing commercial sales. There can be no The Company is subject to risks common to companies in the medical device industry including, but not The Company designs, develops, manufactures and markets a medical device that it refers to as the Viveve System, which is intended for the non-invasive treatment of vaginal introital laxity, for improved sexual function, for vaginal rejuvenation, for use in general surgical procedures for electrocoagulation and hemostasis, and stress urinary incontinence, depending on the relevant country-specific clearance or approval. The Viveve System consists of three four five third In the United States, the Company sells its products primarily through a direct sales force to health care practitioners. Outside the United States, the Company sells through an extensive network of distribution partners. During the year ended December 31, 2021, one December 31, 2020, one no 10% December 31, 2021 2020. As of December 31, 2021, one 10% December 31, 2020, one No 10% Accounts Receivable and Allowance for Doubtful Accounts Accounts receivable are recorded at the invoiced amount and are not six may six not December 31, 2021 2020, During the year ended December 31, 2021, December 31, 2020, Inventory Inventory is stated at the lower of cost or net realizable value. Inventory as of December 31, 2021 $493.000 December 31, 2020 first first not As part of the Company’s recurring revenue rental model, the Company utilizes Viveve Systems transferred from finished goods inventory. The Company is amortizing these units over an estimated useful life of five December 31, 2021 2020. Property and Equipment, net Property and equipment are stated at cost, net of accumulated depreciation and amortization. Depreciation of property and equipment is computed using the straight-line method over their estimated useful lives of three seven Impairment of Long-Lived Assets The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset might not not Revenue from Contracts with Customers Revenue consists primarily of the sale of the Viveve System, single-use treatment tips and ancillary consumables. The Company applies the following five 1 2 3 4 5 Rental revenue is generated through the lease of the Viveve System. The Company’s operating leases for the Viveve System generally have a rental period of6 12 December 31, 2021 2020, December 31, 2021 2020, December 31, 2021, December 31, 2020. December 31, 2020, December 31, 2019. Late in the first 2020 December 31, 2021, 19 second 2020 three 19 In connection with the lease of the Viveve System, the Company offers single-use treatment tips and ancillary consumables that are considered non-lease components. In the contracts with lease and non-lease components, the Company follows the relevant guidance in ASC 606, Sales of our products are subject to regulatory requirements that vary from country to country. The Company has regulatory clearance for differing indications, or can sell its products without a clearance, in many countries throughout the world, including countries within the following regions: North America, Asia Pacific, Europe, the Middle East and Latin America. In the United States, we market and sell primarily through a direct sales force. Outside of the United States, we market and sell primarily through distribution partners. The Company does not Customer Advance Payments From time to time, customers will pay for a portion of the products ordered in advance. Upon receipt of such payments, the Company records the customer advance payment as a component of accrued liabilities. The Company will remove the customer advance payment from accrued liabilities when revenue is recognized upon shipment of the products. Contract Assets and Liabilities The Company continually evaluates whether the revenue generating activities and advanced payment arrangements with customers result in the recognition of contract assets or liabilities. No such assets existed as of December 31, 2021 2020. not December 31, 2021 December 31, 2020, The following table reflects the changes in our customer contract liabilities for the year ended December 31, 2021: December 31, 2021 2020 Change Customer contracts liabilities: Marketing programs $ 7 $ 17 $ (10 ) Total $ 7 $ 17 $ (10 ) Separately, accounts receivable, net represents receivables from contracts with customers. Significant Financing Component The Company applies the practical expedient to not not one December 31, 2021 2020, not Contract Costs The Company expects that commissions paid to obtain subscriptions are recoverable and has therefore capitalized them as a contract cost in the amount of $84,000 and $132,000 at December 31, 2021 2020, December 31, 2021 2020, no Shipping and Handling Shipping costs billed to customers are recorded as revenue. Shipping and handling expense related to costs incurred to deliver product are recognized within cost of goods sold. The Company accounts for shipping and handling activities that occur after control has transferred as a fulfillment cost as opposed to a separate performance obligation, and the costs of shipping and handling are recognized concurrently with the related revenue. Revenue by Geographic Area: Management has determined that the sales by geography is a key indicator for understanding the Company’s financials because of the different sales and business models that are required in the various regions of the world (including regulatory, selling channels, pricing, customers and marketing efforts). The following table presents the revenue from unaffiliated customers disaggregated by geographic area for the year ended December 31, 2021 2020 Year Ended December 31, 2021 2020 United States $ 3,701 $ 2,537 Asia Pacific 2,647 2,732 Canada 66 110 Europe and Middle East 12 86 Latin America - 14 Total $ 6,426 $ 5,479 The Company determines geographic location of its revenue based upon the destination of the shipments of its products. Investments in Unconsolidated Affiliates The Company uses the equity method to account for its investments in entities that it does not 1 2 3 three not The Company assesses the potential impairment of the equity method investments when indicators such as a history of operating losses, a negative earnings and cash flow outlook, and the financial condition and prospects for the investee’s business segment might indicate a loss in value. The carrying value of the investments is reviewed annually for changes in circumstances or the occurrence of events that suggest the investment may not December 31, 2021 2020, no Product Warranty The Company’s products sold to customers are generally subject to warranties between one three not Advertising Costs Advertising costs are charged to selling, general and administrative expenses as incurred. Advertising expenses, which are recorded in selling, general and administrative expenses, were immaterial for the years ended December 31, 2021 2020. Research and Development Research and development costs are charged to operations as incurred. Research and development costs include, but are not Income Taxes The provision for income taxes is determined using the asset and liability approach of accounting for income taxes. Under this approach, deferred taxes represent the future tax consequences expected to occur when the reported amounts of assets and liabilities are recovered or paid. The provision for income taxes represents income taxes paid or payable for the current year plus the change in deferred taxes during the year. Deferred taxes result from differences between the financial and tax basis of the Company’s assets and liabilities and are adjusted for changes in tax rates and tax laws when changes are enacted. Valuation allowances are recorded to reduce deferred tax assets when it is more likely than not not The Company must assess the likelihood that the Company’s deferred tax assets will be recovered from future taxable income, and to the extent the Company believes that recovery is not December 31, 2021 2020. not not The Company recognizes in the financial statements the impact of a tax position, if that position is more likely than not not 12 Accounting for Stock-Based Compensation Share-based compensation cost is measured at grant date, based on the fair value of the award, and is recognized as expense over the employee’s service period. The Company recognizes compensation expense on a straight-line basis over the requisite service period of the award. The Company determined that the Black-Scholes option pricing model is the most appropriate method for determining the estimated fair value for stock options and purchase rights under the employee stock purchase plan. The Black-Scholes option pricing model requires the use of highly subjective and complex assumptions which determine the fair value of share-based awards, including the option’s expected term and the price volatility of the underlying stock. Equity instruments issued to nonemployees are recorded in the same manner as similar instruments issued to employees. Comprehensive Loss Comprehensive loss represents the changes in equity of an enterprise, other than those resulting from stockholder transactions. Accordingly, comprehensive loss may December 31, 2021 2020, Net Loss per Share The Company’s basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding for the period. The diluted net loss per share is computed by giving effect to all potentially dilutive common stock equivalents outstanding during the period. For purposes of this calculation, stock options and warrants to purchase common stock and restricted common stock awards are considered common stock equivalents. For periods in which the Company has reported net losses, diluted net loss per share is the same as basic net loss per share, since dilutive common shares are not The following securities were excluded from the calculation of net loss per share because the inclusion would be anti-dilutive. Year Ended December 31, 2021 2020 Convertible preferred stock: Series A convertible preferred stock (a) - - Series B convertible preferred stock (b) 2,647,320 2,341,111 Series C convertible preferred stock (c) - - Warrants to purchase common stock 9,793,599 1,728,725 Stock options to purchase common stock 3,173,103 986,399 Deferred restricted common stock units 674,000 - Deferred restricted common stock awards 228 234 (a) Each share of Series A convertible preferred stock was convertible at any time at the holder's option into one December 2020, December 31, 2021, no (b) As of December 31, 2021 2020, 1 not (c) Each share of Series C preferred stock is convertible at any time at the holder’s option into one December 31, 2021, Recently Issued Accounting Standards In June 2016, 2016 13, 326 not 2016 13 December 15, 2022 In December 2019, 2019 12, 740 December 15, 2020, January 1, 2021 not We have reviewed other recent accounting pronouncements and concluded they are either not no

Note 3 - Fair Value Measurement

Note 3 - Fair Value Measurements	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Fair Value Disclosures [Text Block]	3. Fair Value Measurements The Company recognizes and discloses the fair value of its assets and liabilities using a hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to valuations based upon unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 3 Level 1 Inputs used to measure fair value are unadjusted quoted prices that are available in active markets for the identical assets or liabilities as of the reporting date. Therefore, determining fair value for Level 1 not not Level 2 Pricing is provided by third not Level 3 Inputs used to measure fair value are unobservable inputs that are supported by little or no 3 Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability. There were no December 31, 2021 2020. The carrying amounts of the Company’s financial assets and liabilities, including cash and cash equivalents, accounts receivable, accounts payable, and accrued expenses as of December 31, 2021 2020 There were no

Note 4 - Property and Equipment

Note 4 - Property and Equipment, Net	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	4. Property and Equipment, Net Property and equipment, net, consisted of the following as of December 31, 2021 2020 Life December 31, (in years) 2021 2020 Medical equipment 5 $ 2,628 $ 3,111 Rental equipment 5 1,118 1,812 Computer equipment 3 157 242 Leasehold Improvements 3 122 122 Furniture and fixtures 7 244 386 Software 3 35 25 4,304 5,698 Less: Accumulated depreciation and amortization (2,750 ) (2,939 ) Property and equipment, net $ 1,554 $ 2,759 Depreciation and amortization expense for the years ended December 31, 2021 2020

Note 5 - Investment in Limited

Note 5 - Investment in Limited Liability Company	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Equity Method Investments and Joint Ventures Disclosure [Text Block]	5. Investment in Limited Liability Company On August 8, 2017, In connection with the Distributorship Agreement, the Company also entered into a Membership Unit Subscription Agreement with ICM and the associated limited liability company operating agreement of ICM, pursuant to which the Company invested $2,500,000 in, and acquired membership units of, ICM. This investment has been recorded in investment in a limited liability company in the consolidated balance sheets. The Company used the equity method to account for the investment in ICM because the Company does not December 31, 2021, three December 31, 2021 2020, In February 2019, no During the years ended December 31, 2021 2020, December 31, 2021 2020, December 31, 2021 2020.

Note 6 - Accrued Liabilities

Note 6 - Accrued Liabilities	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	6. Accrued Liabilities Accrued liabilities consisted of the following as of December 31, 2021 2020 December 31, 2021 2020 Accrued bonuses $ 1,209 $ 744 Accrued payroll and other related expenses 495 473 Deferred revenue - subscription rental program 448 345 Accrued clinical trial costs 337 91 Current operating lease liabilities 225 132 Accrued professional fees 120 290 Other accruals 219 341 Total accrued liabilities $ 3,053 $ 2,416

Note 7 - Note Payable

Note 7 - Note Payable	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Debt Disclosure [Text Block]	7. Note Payable On May 22, 2017, December 12, 2017 November 29, 2018 ( “2017 December 29, 2017, In connection with the 2017 two 12 Under the 2017 November 12, 2019 six four 2017 may, As security for its obligations under the 2017 The terms of the 2017 2017 On November 12, 2019, 2017 No. 3” 12 one The Amendment No. 3 2017 ● repayment provisions were amended such that repayment is permitted only with, or after, the redemption in full of the Series B convertible preferred stock issued to CRG; ● the interest only payment period and the period during which the Company may 23rd first no 2017 ● modified certain of the covenants, including (i) to permit issuance of the Series B convertible preferred stock and any preferred stock issued in the equity financing and the exercise and performance by the Company of its rights and obligations in connection with such CRG preferred stock and any preferred stock issued in the equity financing, (ii) eliminate the Company’s ability to enter into permitted acquisitions, (iii) further restrict the incurrence of additional indebtedness and removal of the equity cure right, and (iv) eliminate the minimum revenue requirement; and ● the back-end facility fee on the aggregate remaining principal balance on the term loan shall be increased from 5% to 25%. Pursuant to the amendment, the Company paid interest in-kind of $602,000 and $532,000 during the years ended December 31, 2021 2020, As of December 31, 2021, As of December 31, 2021 2020, March 31, 2023. As of December 31, 2021, Year Ending December 31, 2022 $ - 2023 5,992 Total Payments 5,992 Less: Amount representing interest (863 ) Present value of obligations 5,129 Less: Unamortized debt discount (5 ) Note payable, noncurrent portion $ 5,124

Note 8 - Paycheck Protection Pr

Note 8 - Paycheck Protection Program Loan	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Long-term Debt [Text Block]	8. Paycheck Protection Program Loan The Paycheck Protection Program (“PPP”) was established under the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) and is administered by the U.S. Small Business Administration (“SBA”). On April 24, 2020, 1.00% two ten No In October 2020, 8 24 six 10 16 no two October 2020. In May 2021, December 31, 2021

Note 9 - Leases

Note 9 - Leases	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Lessee, Operating Leases [Text Block]	9. Leases Lessee: The following information pertains to those operating lease agreements where the Company is the lessee. On February 1, 2017, January 26, 2017. June 1, 2017 May 2020. November 2019, one May 2021. June 2017. The monthly base rent under the Sublease was equal to $20.50 per rentable square foot of the Sublease Premises during the first second third In March 2021, March 31, 2024. second third June 2021. In September 2018, September 2018 November 2020. In October 2020, December 2020 December 2023. Operating lease rentals are expensed on a straight-line basis over the life of the lease beginning on the date the Company takes possession of the property. At lease inception, the Company determines the lease term by assuming the exercise of those renewal options that are reasonably assured. The lease term is used to determine whether a lease is financing or operating and is used to calculate straight-line rent expense. Additionally, the depreciable life of leasehold improvements is limited by the expected lease term. Leases with an initial term of 12 not The following table reflects the Company's lease assets and lease liabilities at December 31, 2021 2020 December 31, 2021 2020 Assets: Operating lease right-of-use assets $ 534 $ 130 Liabilities: Current operating lease liabilities $ 225 $ 132 Noncurrent operating lease liabilities 327 - $ 552 $ 132 The operating lease right-of-use assets are included in other assets on the consolidated balance sheets. The operating lease liabilities are included in accrued liabilities and other noncurrent liabilities on the consolidated balance sheets. The operating lease expense for the years ended December 31, 2021 2020 As of December 31, 2021, Year Ending December 31, 2022 $ 282 2023 287 2024 67 Total lease payments 636 Less: Amount representing interest (84 ) Present value of lease liabilities $ 552 The weighted average remaining lease term was approximately 27 months as of December 31, 2021. December 31, 2021 Lessor: The following information pertains to those operating lease agreements where the Company is the lessor. As of December 31, 2021, Year Ending December 31, 2022 $ 448 2023 4 Total $ 452 As of December 31, 2021, December 31, 2021 2020

Note 10 - Commitments and Conti

Note 10 - Commitments and Contingencies	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	10. Commitments and Contingencies Indemnification Agreements The Company enters into standard indemnification arrangements in the ordinary course of business. Pursuant to these arrangements, the Company indemnifies, holds harmless and agrees to reimburse the indemnified parties for losses suffered or incurred by the indemnified party, in connection with performance of services within the scope of the agreement, breach of the agreement by the Company, or noncompliance of regulations or laws by the Company, in all cases provided the indemnified party has not not not Loss Contingencies The Company is or has been subject to proceedings, lawsuits and other claims arising in the ordinary course of business. The Company evaluates contingent liabilities, including threatened or pending litigation, for potential losses. If the potential loss from any claim or legal proceeding is considered probable and the amount can be estimated, the Company accrues a liability for the estimated loss. Because of uncertainties related to these matters, accruals are based upon the best information available. For potential losses for which there is a reasonable possibility (meaning the likelihood is more than remote but less than probable) that a loss exists, the Company will disclose an estimate of the potential loss or range of such potential loss or include a statement that an estimate of the potential loss cannot be made. As additional information becomes available, the Company reassesses the potential liability related to pending claims and litigation and may not

Note 11 - Preferred Stock

Note 11 - Preferred Stock	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Preferred Stock [Text Block]	11. Preferred Stock Series A Convertible Preferred Stock On December 16, 2020, Series B Convertible Preferred Stock As previously reported (see Note 7 In connection with the CRG debt conversion, on November 26, 2019, December 31, 2020, December 31, 2021, December 31, 2021, December 31, 2021. As of December 31, 2021 December 31, 2020, 1 not The shares of Series B convertible preferred stock have no The Series B convertible preferred stock also provides that for so long as any shares are outstanding, the consent of the holders of the Series B convertible preferred stockholders would be required to amend the Company’s organizational documents, approve any merger, sale of assets, or other major corporate transaction, or incur additional indebtedness, among other items. Series C Convertible Preferred Stock In connection with the closing of the public offering on January 19, 2021, With certain exceptions, as described in the Series C Certificate of Designation, the shares of Series C convertible preferred stock have no Each share of Series C convertible preferred stock is convertible at any time at the holder’s option into one A total of 2,450,880 shares of Series C convertible preferred stock were issued in the January 2021 January 2021,

Note 12 - Common Stock

Note 12 - Common Stock	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	12. Common Stock Purchase Agreement with Lincoln Park Capital, LLC On June 8, 2020, The Purchase Agreement limited the Company’s sale of shares of common stock to LPC to 301,762 shares of common stock, representing 19.99% of the shares of the common stock outstanding on the date of the Purchase Agreement unless (i) shareholder approval was obtained to issue more than such amount or (ii) the average price of all applicable sales of common stock to LPC under the Purchase Agreement equaled or exceeded $6.46 per share, which represented the lower of (a) the closing price of our common stock on the Nasdaq Capital Market immediately preceding the date of the Purchase Agreement or (b) the average of the closing price of the common stock on the Nasdaq Capital Market for the five June 9, 2020, no On March 31, 2021, first five On May 4, 2021, On June 23, 2021, As of December 31, 2021, 2021 On January 19, 2021, “January 2021 The offering comprised of: ( 1 one one one fifth 2 one one one fifth A total of 2,450,880 shares of Series C convertible preferred stock were issued in the January 2021 January 2021, Warrants to purchase a total of 8,117,640 shares of common stock were issued in the January 2021 February March 2021, January 2021 December 31, 2021, January 2021 Restricted Common Shares There were no restricted common shares issued during the year ended December 31, 2021. The activity of restricted common shares for the year ended December 31, 2020 In March 2020, In June 2020, In September 2020, Warrants for Common Stock As of December 31, 2021, Issuance Date Exercisable for Expiration Date Exercise Price Number of Shares Outstanding Under Warrants February 2015 Common Shares February 17, 2025 $ 4,000.00 79 March 2015 Common Shares March 26, 2025 $ 2,720.00 2 May 2015 Common Shares May 12, 2025 $ 4,240.00 37 December 2015 Common Shares December 16, 2025 $ 5,600.00 31 April 2016 Common Shares April 1, 2026 $ 6,080.00 25 June 2016 Common Shares June 20, 2026 $ 4,980.00 101 May 2017 Common Shares May 25, 2027 $ 9,500.00 223 November 2019 Common Shares November 26, 2024 $ 18.36 989,379 November 2019 Common Shares November 26, 2024 $ 2.82 285,632 April 2020 Common Shares April 21, 2025 $ 2.82 413,210 January 2021 Common Shares January 19, 2026 $ 3.40 8,104,880 9,793,599 As of December 31, 2020, Issuance Date Exercisable for Expiration Date Exercise Price Number of Shares Outstanding Under Warrants February 2015 Common Shares February 17, 2025 $ 4,000.00 79 March 2015 Common Shares March 26, 2025 $ 2,720.00 2 May 2015 Common Shares May 12, 2025 $ 4,240.00 37 December 2015 Common Shares December 16, 2025 $ 5,600.00 31 April 2016 Common Shares April 1, 2026 $ 6,080.00 25 May 2016 Common Shares May 11, 2021 $ 7,740.00 6 June 2016 Common Shares June 20, 2026 $ 4,980.00 101 May 2017 Common Shares May 25, 2027 $ 9,500.00 223 November 2019 Common Shares November 26, 2024 $ 6.10 325,632 November 2019 Common Shares November 26, 2024 $ 18.36 989,379 April 2020 Common Shares April 21, 2025 $ 6.37 413,210 1,728,725 In connection with the 2017 ten December 31, 2021 2020, December 31, 2021, In connection with the CRG Debt Conversion, CRG received warrants exercisable for 989,379 shares of common stock, an amount equal to 15% of our common stock on a fully diluted basis after taking the November 2019 five In February 2020, On April 15, 2020, $6.10 $15.50 April 15, 2020, 718, 718 Immediately before Modification Immediately After Modification Exercise price $ 15.50 $ 6.10 Common stock price $ 6.30 $ 6.30 Expected term (in years) 2.8 2.8 Average volatility 97 % 97 % Risk-free interest rate 0.27 % 0.27 % Dividend yield 0 % 0 % On April 16, 2020, In conjunction, the Company also agreed to issue new Series A- 2 2 five 2 2 of.35% five 2 2 April 20, 2020. 2020 In May 2020, In June 2020, In August 2020, In August 2020, 2 2 In September 2020, In connection with the January 2021 one fifth As a result of the closing of the January 2021 2 2 2 2 no 2 2 Series B Warrants Immediately before Modification Immediately After Modification Exercise price $ 6.10 $ 3.40 Common stock price $ 3.19 $ 3.19 Expected term (in years) 3.9 3.9 Average volatility 90 % 90 % Risk-free interest rate 0.33 % 0.33 % Dividend yield 0 % 0 % Series A-2 and B-2 Warrants Immediately before Modification Immediately After Modification Exercise price $ 6.37 $ 3.40 Common stock price $ 3.19 $ 3.19 Expected term (in years) 4.3 4.3 Average volatility 90 % 90 % Risk-free interest rate 0.33 % 0.33 % Dividend yield 0 % 0 % On May 4, 2021, 2 2 no 2 2 Series B, A-2 and B-2 Warrants Immediately before Modification Immediately After Modification Exercise price $ 3.40 $ 2.82 Common stock price $ 3.01 $ 3.01 Expected term (in years) 3.6 3.6 Average volatility 80 % 80 % Risk-free interest rate 0.58 % 0.58 % Dividend yield 0 % 0 % The incremental fair value of the Series B, A- 2 2 In February 2021, January 2021 In March 2021, January 2021 During the year ended December 31, 2021, December 31, 2020, No shares issuable pursuant to warrants have been cancelled during the year ended December 31, 2021 2020. A total of 6 shares issuable pursuant to warrants expired during the year ended December 31, 2021. December 31, 2020. As of December 31, 2021, As of December 31, 2021, 2 2 As of December 31, 2021, January 2021

Note 13 - Summary of Stock Opti

Note 13 - Summary of Stock Options	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Share-based Payment Arrangement [Text Block]	13. Summary of Stock Options Stock Option Plans The Company has issued equity awards in the form of stock options (both incentive stock options and non-qualified stock options) and deferred restricted stock awards or units, from two 2006 “2006 2013 “2013 As of December 31, 2021, 2006 The 2013 2013 2013 may may may 2013 may not may four may 424 no not five On August 22, 2016, 2013 first January, 2013 In January 2020, 2020 2013 1,187,253 January 1, 2020. In January 2021, 2013 2013 In June 2021, 2013 17 2013 December 31, 2021. As of December 31, 2021, 2013 Activity under the 2006 2013 Number of Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Term (years) Aggregate Intrinsic Value Options outstanding, January 1, 2021 986,399 $ 19.10 8.9 $ 675 Options granted 2,251,000 $ 2.73 Options exercised - Options canceled (64,296 ) $ 17.85 Options outstanding, December 31, 2021 3,173,103 $ 7.51 9.0 $ - Vested and exercisable and expected to vest, December 31, 2021 2,947,472 $ 7.83 9.0 $ - Vested and exercisable, December 31, 2021 774,800 $ 18.81 8.5 $ - The aggregate intrinsic value reflects the difference between the exercise price of the underlying stock options and the Company’s closing share price as of December 31, 2021. The options outstanding and exercisable as of December 31, 2021 Range of Exercise Prices Number Outstanding as of December 31, 2021 Weighted Average Exercise Price Weighted Average Remaining Contractual Term (Years) Number Exercisable as of December 31, 2021 Weighted Average Exercise Price $2.28 - $2.96 2,208,063 $ 2.73 9.5 259,301 $ 2.73 $3.06 - $3.40 10,000 $ 3.20 9.2 - $ - $4.45 - $4.80 11,900 $ 4.72 8.9 3,088 $ 4.71 $5.10 - $5.40 88,000 $ 5.28 8.8 62,219 $ 5.34 $6.90 - $6.90 5,400 $ 6.90 8.3 2,364 $ 6.90 $8.60 - $8.91 830,825 $ 8.69 7.9 433,263 $ 8.69 $10.90 - $13.60 15,500 $ 12.64 8.2 11,271 $ 13.00 $380.00 - $9,920.00 3,415 $ 2,873.63 6.2 3,294 $ 2,911.12 Total: 3,173,103 $ 7.51 9.0 774,800 $ 18.81 Deferred Restricted Stock Units As of December 31, 2021, 2013 In January 2021, 2013 second During the year ended December 31, 2021, During the year ended December 31, 2020, 2013 Deferred Restricted Stock Awards As of December 31, 2021, 2013 During the year ended December 31, 2021 2020, During the year ended December 31, 2021 2020, 2017 In August 2017, 2017 “2017 may 2017 first three The activity of the Company’s 2017 December 31, 2020 ● The tenth 2017 January 1, 2020 March 31, 2020, March 31, 2020 ● The eleventh 2017 April 1, 2020 June 30, 2020, June 30, 2020 ● The twelfth 2017 July 1, 2020, September 30, 2020, September 30, 2020 In September 2020, 2017 twelfth September 30, 2020. In June 2021, 2017 Following the Company’s annual stockholders’ meeting, the board of directors approved to reactivate the ESPP effective with the offering period beginning on July 1, 2021. The activity of the Company’s 2017 December 31, 2021 ● The thirteenth 2017 July 1, 2021, September 30, 2021, September 30, 2021 ● The fourteenth 2017 October 1, 2021, December 31, 2021, December 31, 2021 The Company estimated the fair value of purchase rights under the ESPP using the Black-Scholes option valuation model and the straight-line attribution approach. As of December 31, 2021, 2017 Stock-Based Compensation During the years ended December 31, 2021 2020, December 31, 2021 2020. The Company estimated the fair value of stock options using the Black-Scholes option pricing model. The fair value of stock options is being amortized on a straight-line basis over the requisite service period of the awards. The fair value of stock options granted was estimated using the following weighted average assumptions: Year Ended December 31, 2021 2020 Expected term (in years) 6 5 Average volatility 76 % 82 % Risk-free interest rate 0.97 % 0.37 % Dividend yield 0 % 0 % Option-pricing models require the input of various subjective assumptions, including the option’s expected life and the price volatility of the underlying stock. The expected stock price volatility is based on analysis of the Company’s stock price history over a period commensurate with the expected term of the options, trading volume of comparable companies’ stock, look-back volatilities and the Company specific events that affected volatility in a prior period. The expected term of stock options represents the weighted average period the stock options are expected to remain outstanding and is based on the history of exercises and cancellations on all past option grants made by the Company, the contractual term, the vesting period and the expected remaining term of the outstanding options. The risk-free interest rate is based on the U.S. Treasury interest rates whose term is consistent with the expected life of the stock options. No dividend yield is included as the Company has not not The following table shows stock-based compensation expense for options, RSUs and ESPP shares included in the consolidated statements of operations for the years ended December 31, 2021 2020 Year Ended December 31, 2021 2020 Cost of revenue $ 265 $ 208 Research and development 456 325 Selling, general and administrative 3,058 2,118 Total $ 3,779 $ 2,651 As of December 31, 2021, As of December 31, 2021,

Note 14 - Income Taxes

Note 14 - Income Taxes	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Income Tax Disclosure [Text Block]	14. Income Taxes No provision for income taxes has been recorded due to the net operating losses incurred from inception to date, for which no The Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) was enacted on March 27, 2020 The Company’s effective tax rate is 0% for the years ended December 31, 2021 2020. A reconciliation of the U.S. statutory income tax rate to the Company’s effective tax rate is as follows: Year Ended December 31, 2021 2020 Income tax benefit at statutory rate (21 )% (21 )% State income taxes, net of federal benefit (3 )% (3 )% Change in valuation allowance 21 % 20 % Other 3 % 4 % Effective tax rate 0 % 0 % The components of the Company’s net deferred tax assets and liabilities are as follows (in thousands): Year Ended December 31, 2021 2020 Deferred tax assets: Net operating loss carryforwards $ 25,092 $ 20,891 Capitalized start up costs 2,511 2,866 Research and development credits 781 631 Accruals and reserves 1,537 773 Fixed assets and depreciation 124 291 Total deferred tax assets 30,045 25,452 Deferred tax liabilities: Valuation allowance (30,045 ) (25,452 ) Net deferred tax assets $ - $ - The Company has recorded a full valuation allowance for its deferred tax assets based on its past losses and the uncertainty regarding the ability to project future taxable income. The valuation allowance increased by approximately $4,593,000 during the year ended December 31, 2021 December 31, 2020. As of December 31, 2021, not 2028. The Company has California research and development tax credits of approximately $768,000. The credits have no 2028. Utilization of the NOL and research and development credit carryforwards may 382 1986, may 382, 50 three not November 2019, January 2021 no As of December 31, 2021, not A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows (in thousands): Year Ended December 31, 2021 2020 Balance at the beginning of the year $ 245 $ 223 Additions (deletions) based upon tax positions related to the current year (14 ) 22 Balance at the end of the year $ 231 $ 245 If the ending balance of $231,000 of unrecognized tax benefits as of December 31, 2021 none not twelve may The Company files U.S. federal and state income tax returns with varying statutes of limitations. All tax years since inception remain open to examination due to the carryover of unused net operating losses and tax credits.

Note 15 - Related Party Transac

Note 15 - Related Party Transactions	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	15. Related Party Transactions In June 2006, October 4, 2007. December 31, 2021, December 31, 2021 2020, In August 2017, February 2019, no 5

Note 16 - Segments and Geograph

Note 16 - Segments and Geographic Information	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Segment Reporting Disclosure [Text Block]	16. Segments and Geographic Information The Company’s long-lived assets by geographic area were as follows (in thousands): December 31, 2021 2020 United States $ 1,553 $ 2,622 Asia Pacific - 76 Canada 1 54 Europe - 7 Total $ 1,554 $ 2,759 Long-lived assets, comprised of property and equipment, are reported based on the location of the assets at each balance sheet date.

Note 17 - Subsequent Events

Note 17 - Subsequent Events	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Subsequent Events [Text Block]	17. Subsequent Events 2013 2022 Effective January 1, 2022, 2013 2013 Annual Equity Awards In January 2022, 2013 Retention Bonus On January 18, 2022, two 2022, January 31, 2023. Series C Convertible Preferred Stock On March 14, 2022,

Significant Accounting Policies

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Financial Statement Presentation The consolidated financial statements include the accounts of the Company and our wholly-owned subsidiaries, Viveve, Inc. and Viveve BV. All significant intercompany accounts and transactions have been eliminated in consolidation.
Reclassification, Comparability Adjustment [Policy Text Block]	Reclassification of Prior Year Presentation Certain prior year amounts have been reclassified for consistency with the current period presentation. These reclassifications had no December 31, 2020
Reverse Stock Split, Policy [Policy Text Block]	Reverse Stock Split - December 2020 The Company effected a 1 December 1, 2020. ten one As a result of the reverse stock split, proportionate adjustments were made to the per share exercise price and/or the number of shares issuable upon the exercise or vesting of all then outstanding stock options, deferred restricted stock awards and warrants, which will result in a proportional decrease in the number of shares of the Company’s common stock reserved for issuance upon exercise or vesting of such stock options, deferred restricted stock awards and warrants, and, in the case of stock options and warrants, a proportional increase in the exercise price of all such stock options and warrants. In addition, the number of shares reserved for issuance under the Company’s equity compensation plans immediately prior to the effective date will be reduced proportionately. No fractional shares were issued as a result of the reverse stock split. Stockholders of record who would otherwise have been entitled to receive a fractional share were rounded up to the nearest whole number. The Company issued 5,931 shares of common stock as a result of this rounding adjustment. All of the share numbers, share prices, and exercise prices have been adjusted, on a retroactive basis, to reflect this 1 10
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenue, and expenses and the related disclosure of contingent assets and liabilities. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not may
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents The Company considers all highly liquid investments purchased with an original maturity of three one may,
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentration of Credit Risk and Other Risks and Uncertainties To achieve profitable operations, the Company must successfully develop, manufacture, and market its products. There can be no Most of the Company’s products to date require clearance or approvals from the U.S. Food and Drug Administration (“FDA”) or other international regulatory agencies prior to commencing commercial sales. There can be no The Company is subject to risks common to companies in the medical device industry including, but not The Company designs, develops, manufactures and markets a medical device that it refers to as the Viveve System, which is intended for the non-invasive treatment of vaginal introital laxity, for improved sexual function, for vaginal rejuvenation, for use in general surgical procedures for electrocoagulation and hemostasis, and stress urinary incontinence, depending on the relevant country-specific clearance or approval. The Viveve System consists of three four five third In the United States, the Company sells its products primarily through a direct sales force to health care practitioners. Outside the United States, the Company sells through an extensive network of distribution partners. During the year ended December 31, 2021, one December 31, 2020, one no 10% December 31, 2021 2020. As of December 31, 2021, one 10% December 31, 2020, one No 10%
Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]	Accounts Receivable and Allowance for Doubtful Accounts Accounts receivable are recorded at the invoiced amount and are not six may six not December 31, 2021 2020, During the year ended December 31, 2021, December 31, 2020,
Inventory, Policy [Policy Text Block]	Inventory Inventory is stated at the lower of cost or net realizable value. Inventory as of December 31, 2021 $493.000 December 31, 2020 first first not As part of the Company’s recurring revenue rental model, the Company utilizes Viveve Systems transferred from finished goods inventory. The Company is amortizing these units over an estimated useful life of five December 31, 2021 2020.
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment, net Property and equipment are stated at cost, net of accumulated depreciation and amortization. Depreciation of property and equipment is computed using the straight-line method over their estimated useful lives of three seven
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]	Impairment of Long-Lived Assets The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset might not not
Revenue from Contract with Customer [Policy Text Block]	Revenue from Contracts with Customers Revenue consists primarily of the sale of the Viveve System, single-use treatment tips and ancillary consumables. The Company applies the following five 1 2 3 4 5 Rental revenue is generated through the lease of the Viveve System. The Company’s operating leases for the Viveve System generally have a rental period of6 12 December 31, 2021 2020, December 31, 2021 2020, December 31, 2021, December 31, 2020. December 31, 2020, December 31, 2019. Late in the first 2020 December 31, 2021, 19 second 2020 three 19 In connection with the lease of the Viveve System, the Company offers single-use treatment tips and ancillary consumables that are considered non-lease components. In the contracts with lease and non-lease components, the Company follows the relevant guidance in ASC 606, Sales of our products are subject to regulatory requirements that vary from country to country. The Company has regulatory clearance for differing indications, or can sell its products without a clearance, in many countries throughout the world, including countries within the following regions: North America, Asia Pacific, Europe, the Middle East and Latin America. In the United States, we market and sell primarily through a direct sales force. Outside of the United States, we market and sell primarily through distribution partners. The Company does not Customer Advance Payments From time to time, customers will pay for a portion of the products ordered in advance. Upon receipt of such payments, the Company records the customer advance payment as a component of accrued liabilities. The Company will remove the customer advance payment from accrued liabilities when revenue is recognized upon shipment of the products. Contract Assets and Liabilities The Company continually evaluates whether the revenue generating activities and advanced payment arrangements with customers result in the recognition of contract assets or liabilities. No such assets existed as of December 31, 2021 2020. not December 31, 2021 December 31, 2020, The following table reflects the changes in our customer contract liabilities for the year ended December 31, 2021: December 31, 2021 2020 Change Customer contracts liabilities: Marketing programs $ 7 $ 17 $ (10 ) Total $ 7 $ 17 $ (10 ) Separately, accounts receivable, net represents receivables from contracts with customers. Significant Financing Component The Company applies the practical expedient to not not one December 31, 2021 2020, not Contract Costs The Company expects that commissions paid to obtain subscriptions are recoverable and has therefore capitalized them as a contract cost in the amount of $84,000 and $132,000 at December 31, 2021 2020, December 31, 2021 2020, no Shipping and Handling Shipping costs billed to customers are recorded as revenue. Shipping and handling expense related to costs incurred to deliver product are recognized within cost of goods sold. The Company accounts for shipping and handling activities that occur after control has transferred as a fulfillment cost as opposed to a separate performance obligation, and the costs of shipping and handling are recognized concurrently with the related revenue. Revenue by Geographic Area: Management has determined that the sales by geography is a key indicator for understanding the Company’s financials because of the different sales and business models that are required in the various regions of the world (including regulatory, selling channels, pricing, customers and marketing efforts). The following table presents the revenue from unaffiliated customers disaggregated by geographic area for the year ended December 31, 2021 2020 Year Ended December 31, 2021 2020 United States $ 3,701 $ 2,537 Asia Pacific 2,647 2,732 Canada 66 110 Europe and Middle East 12 86 Latin America - 14 Total $ 6,426 $ 5,479 The Company determines geographic location of its revenue based upon the destination of the shipments of its products.
Equity Method Investments [Policy Text Block]	Investments in Unconsolidated Affiliates The Company uses the equity method to account for its investments in entities that it does not 1 2 3 three not The Company assesses the potential impairment of the equity method investments when indicators such as a history of operating losses, a negative earnings and cash flow outlook, and the financial condition and prospects for the investee’s business segment might indicate a loss in value. The carrying value of the investments is reviewed annually for changes in circumstances or the occurrence of events that suggest the investment may not December 31, 2021 2020, no
Standard Product Warranty, Policy [Policy Text Block]	Product Warranty The Company’s products sold to customers are generally subject to warranties between one three not
Advertising Cost [Policy Text Block]	Advertising Costs Advertising costs are charged to selling, general and administrative expenses as incurred. Advertising expenses, which are recorded in selling, general and administrative expenses, were immaterial for the years ended December 31, 2021 2020.
Research and Development Expense, Policy [Policy Text Block]	Research and Development Research and development costs are charged to operations as incurred. Research and development costs include, but are not
Income Tax, Policy [Policy Text Block]	Income Taxes The provision for income taxes is determined using the asset and liability approach of accounting for income taxes. Under this approach, deferred taxes represent the future tax consequences expected to occur when the reported amounts of assets and liabilities are recovered or paid. The provision for income taxes represents income taxes paid or payable for the current year plus the change in deferred taxes during the year. Deferred taxes result from differences between the financial and tax basis of the Company’s assets and liabilities and are adjusted for changes in tax rates and tax laws when changes are enacted. Valuation allowances are recorded to reduce deferred tax assets when it is more likely than not not The Company must assess the likelihood that the Company’s deferred tax assets will be recovered from future taxable income, and to the extent the Company believes that recovery is not December 31, 2021 2020. not not The Company recognizes in the financial statements the impact of a tax position, if that position is more likely than not not 12
Share-based Payment Arrangement [Policy Text Block]	Accounting for Stock-Based Compensation Share-based compensation cost is measured at grant date, based on the fair value of the award, and is recognized as expense over the employee’s service period. The Company recognizes compensation expense on a straight-line basis over the requisite service period of the award. The Company determined that the Black-Scholes option pricing model is the most appropriate method for determining the estimated fair value for stock options and purchase rights under the employee stock purchase plan. The Black-Scholes option pricing model requires the use of highly subjective and complex assumptions which determine the fair value of share-based awards, including the option’s expected term and the price volatility of the underlying stock. Equity instruments issued to nonemployees are recorded in the same manner as similar instruments issued to employees.
Comprehensive Income, Policy [Policy Text Block]	Comprehensive Loss Comprehensive loss represents the changes in equity of an enterprise, other than those resulting from stockholder transactions. Accordingly, comprehensive loss may December 31, 2021 2020,
Earnings Per Share, Policy [Policy Text Block]	Net Loss per Share The Company’s basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding for the period. The diluted net loss per share is computed by giving effect to all potentially dilutive common stock equivalents outstanding during the period. For purposes of this calculation, stock options and warrants to purchase common stock and restricted common stock awards are considered common stock equivalents. For periods in which the Company has reported net losses, diluted net loss per share is the same as basic net loss per share, since dilutive common shares are not The following securities were excluded from the calculation of net loss per share because the inclusion would be anti-dilutive. Year Ended December 31, 2021 2020 Convertible preferred stock: Series A convertible preferred stock (a) - - Series B convertible preferred stock (b) 2,647,320 2,341,111 Series C convertible preferred stock (c) - - Warrants to purchase common stock 9,793,599 1,728,725 Stock options to purchase common stock 3,173,103 986,399 Deferred restricted common stock units 674,000 - Deferred restricted common stock awards 228 234 (a) Each share of Series A convertible preferred stock was convertible at any time at the holder's option into one December 2020, December 31, 2021, no (b) As of December 31, 2021 2020, 1 not (c) Each share of Series C preferred stock is convertible at any time at the holder’s option into one December 31, 2021,
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Issued Accounting Standards In June 2016, 2016 13, 326 not 2016 13 December 15, 2022 In December 2019, 2019 12, 740 December 15, 2020, January 1, 2021 not We have reviewed other recent accounting pronouncements and concluded they are either not no

Note 2 - Summary of Significa_2

Note 2 - Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2021
Notes Tables
Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]	December 31, 2021 2020 Change Customer contracts liabilities: Marketing programs $ 7 $ 17 $ (10 ) Total $ 7 $ 17 $ (10 )
Revenue from External Customers by Geographic Areas [Table Text Block]	Year Ended December 31, 2021 2020 United States $ 3,701 $ 2,537 Asia Pacific 2,647 2,732 Canada 66 110 Europe and Middle East 12 86 Latin America - 14 Total $ 6,426 $ 5,479
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Year Ended December 31, 2021 2020 Convertible preferred stock: Series A convertible preferred stock (a) - - Series B convertible preferred stock (b) 2,647,320 2,341,111 Series C convertible preferred stock (c) - - Warrants to purchase common stock 9,793,599 1,728,725 Stock options to purchase common stock 3,173,103 986,399 Deferred restricted common stock units 674,000 - Deferred restricted common stock awards 228 234

Note 4 - Property and Equipme_2

Note 4 - Property and Equipment, Net (Tables)	12 Months Ended
	Dec. 31, 2021
Notes Tables
Property, Plant and Equipment [Table Text Block]	Life December 31, (in years) 2021 2020 Medical equipment 5 $ 2,628 $ 3,111 Rental equipment 5 1,118 1,812 Computer equipment 3 157 242 Leasehold Improvements 3 122 122 Furniture and fixtures 7 244 386 Software 3 35 25 4,304 5,698 Less: Accumulated depreciation and amortization (2,750 ) (2,939 ) Property and equipment, net $ 1,554 $ 2,759

Note 6 - Accrued Liabilities (T

Note 6 - Accrued Liabilities (Tables)	12 Months Ended
	Dec. 31, 2021
Notes Tables
Schedule of Accrued Liabilities [Table Text Block]	December 31, 2021 2020 Accrued bonuses $ 1,209 $ 744 Accrued payroll and other related expenses 495 473 Deferred revenue - subscription rental program 448 345 Accrued clinical trial costs 337 91 Current operating lease liabilities 225 132 Accrued professional fees 120 290 Other accruals 219 341 Total accrued liabilities $ 3,053 $ 2,416

Note 7 - Note Payable (Tables)

Note 7 - Note Payable (Tables)	12 Months Ended
	Dec. 31, 2021
The 2017 Loan Agreement [Member]
Notes Tables
Schedule of Debt [Table Text Block]	Year Ending December 31, 2022 $ - 2023 5,992 Total Payments 5,992 Less: Amount representing interest (863 ) Present value of obligations 5,129 Less: Unamortized debt discount (5 ) Note payable, noncurrent portion $ 5,124

Note 9 - Leases (Tables)

Note 9 - Leases (Tables)	12 Months Ended
	Dec. 31, 2021
Notes Tables
Lessee, Lease Assets and Liabilities [Table Text Block]	December 31, 2021 2020 Assets: Operating lease right-of-use assets $ 534 $ 130 Liabilities: Current operating lease liabilities $ 225 $ 132 Noncurrent operating lease liabilities 327 - $ 552 $ 132
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	Year Ending December 31, 2022 $ 282 2023 287 2024 67 Total lease payments 636 Less: Amount representing interest (84 ) Present value of lease liabilities $ 552
Lessor, Operating Lease, Payment to be Received, Fiscal Year Maturity [Table Text Block]	Year Ending December 31, 2022 $ 448 2023 4 Total $ 452

Note 12 - Common Stock (Tables)

Note 12 - Common Stock (Tables)	12 Months Ended
	Dec. 31, 2021
Notes Tables
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Issuance Date Exercisable for Expiration Date Exercise Price Number of Shares Outstanding Under Warrants February 2015 Common Shares February 17, 2025 $ 4,000.00 79 March 2015 Common Shares March 26, 2025 $ 2,720.00 2 May 2015 Common Shares May 12, 2025 $ 4,240.00 37 December 2015 Common Shares December 16, 2025 $ 5,600.00 31 April 2016 Common Shares April 1, 2026 $ 6,080.00 25 June 2016 Common Shares June 20, 2026 $ 4,980.00 101 May 2017 Common Shares May 25, 2027 $ 9,500.00 223 November 2019 Common Shares November 26, 2024 $ 18.36 989,379 November 2019 Common Shares November 26, 2024 $ 2.82 285,632 April 2020 Common Shares April 21, 2025 $ 2.82 413,210 January 2021 Common Shares January 19, 2026 $ 3.40 8,104,880 9,793,599 Issuance Date Exercisable for Expiration Date Exercise Price Number of Shares Outstanding Under Warrants February 2015 Common Shares February 17, 2025 $ 4,000.00 79 March 2015 Common Shares March 26, 2025 $ 2,720.00 2 May 2015 Common Shares May 12, 2025 $ 4,240.00 37 December 2015 Common Shares December 16, 2025 $ 5,600.00 31 April 2016 Common Shares April 1, 2026 $ 6,080.00 25 May 2016 Common Shares May 11, 2021 $ 7,740.00 6 June 2016 Common Shares June 20, 2026 $ 4,980.00 101 May 2017 Common Shares May 25, 2027 $ 9,500.00 223 November 2019 Common Shares November 26, 2024 $ 6.10 325,632 November 2019 Common Shares November 26, 2024 $ 18.36 989,379 April 2020 Common Shares April 21, 2025 $ 6.37 413,210 1,728,725
Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]	Immediately before Modification Immediately After Modification Exercise price $ 15.50 $ 6.10 Common stock price $ 6.30 $ 6.30 Expected term (in years) 2.8 2.8 Average volatility 97 % 97 % Risk-free interest rate 0.27 % 0.27 % Dividend yield 0 % 0 % Series B Warrants Immediately before Modification Immediately After Modification Exercise price $ 6.10 $ 3.40 Common stock price $ 3.19 $ 3.19 Expected term (in years) 3.9 3.9 Average volatility 90 % 90 % Risk-free interest rate 0.33 % 0.33 % Dividend yield 0 % 0 % Series A-2 and B-2 Warrants Immediately before Modification Immediately After Modification Exercise price $ 6.37 $ 3.40 Common stock price $ 3.19 $ 3.19 Expected term (in years) 4.3 4.3 Average volatility 90 % 90 % Risk-free interest rate 0.33 % 0.33 % Dividend yield 0 % 0 % Series B, A-2 and B-2 Warrants Immediately before Modification Immediately After Modification Exercise price $ 3.40 $ 2.82 Common stock price $ 3.01 $ 3.01 Expected term (in years) 3.6 3.6 Average volatility 80 % 80 % Risk-free interest rate 0.58 % 0.58 % Dividend yield 0 % 0 %

Note 13 - Summary of Stock Op_2

Note 13 - Summary of Stock Options (Tables)	12 Months Ended
	Dec. 31, 2021
Notes Tables
Share-based Payment Arrangement, Option, Activity [Table Text Block]	Number of Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Term (years) Aggregate Intrinsic Value Options outstanding, January 1, 2021 986,399 $ 19.10 8.9 $ 675 Options granted 2,251,000 $ 2.73 Options exercised - Options canceled (64,296 ) $ 17.85 Options outstanding, December 31, 2021 3,173,103 $ 7.51 9.0 $ - Vested and exercisable and expected to vest, December 31, 2021 2,947,472 $ 7.83 9.0 $ - Vested and exercisable, December 31, 2021 774,800 $ 18.81 8.5 $ -
Share-based Payment Arrangement, Option, Exercise Price Range [Table Text Block]	Range of Exercise Prices Number Outstanding as of December 31, 2021 Weighted Average Exercise Price Weighted Average Remaining Contractual Term (Years) Number Exercisable as of December 31, 2021 Weighted Average Exercise Price $2.28 - $2.96 2,208,063 $ 2.73 9.5 259,301 $ 2.73 $3.06 - $3.40 10,000 $ 3.20 9.2 - $ - $4.45 - $4.80 11,900 $ 4.72 8.9 3,088 $ 4.71 $5.10 - $5.40 88,000 $ 5.28 8.8 62,219 $ 5.34 $6.90 - $6.90 5,400 $ 6.90 8.3 2,364 $ 6.90 $8.60 - $8.91 830,825 $ 8.69 7.9 433,263 $ 8.69 $10.90 - $13.60 15,500 $ 12.64 8.2 11,271 $ 13.00 $380.00 - $9,920.00 3,415 $ 2,873.63 6.2 3,294 $ 2,911.12 Total: 3,173,103 $ 7.51 9.0 774,800 $ 18.81
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Year Ended December 31, 2021 2020 Expected term (in years) 6 5 Average volatility 76 % 82 % Risk-free interest rate 0.97 % 0.37 % Dividend yield 0 % 0 %
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]	Year Ended December 31, 2021 2020 Cost of revenue $ 265 $ 208 Research and development 456 325 Selling, general and administrative 3,058 2,118 Total $ 3,779 $ 2,651

Note 14 - Income Taxes (Tables)

Note 14 - Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2021
Notes Tables
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	Year Ended December 31, 2021 2020 Income tax benefit at statutory rate (21 )% (21 )% State income taxes, net of federal benefit (3 )% (3 )% Change in valuation allowance 21 % 20 % Other 3 % 4 % Effective tax rate 0 % 0 %
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	Year Ended December 31, 2021 2020 Deferred tax assets: Net operating loss carryforwards $ 25,092 $ 20,891 Capitalized start up costs 2,511 2,866 Research and development credits 781 631 Accruals and reserves 1,537 773 Fixed assets and depreciation 124 291 Total deferred tax assets 30,045 25,452 Deferred tax liabilities: Valuation allowance (30,045 ) (25,452 ) Net deferred tax assets $ - $ -
Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]	Year Ended December 31, 2021 2020 Balance at the beginning of the year $ 245 $ 223 Additions (deletions) based upon tax positions related to the current year (14 ) 22 Balance at the end of the year $ 231 $ 245

Note 16 - Segments and Geogra_2

Note 16 - Segments and Geographic Information (Tables)	12 Months Ended
	Dec. 31, 2021
Notes Tables
Long-lived Assets by Geographic Areas [Table Text Block]	December 31, 2021 2020 United States $ 1,553 $ 2,622 Asia Pacific - 76 Canada 1 54 Europe - 7 Total $ 1,554 $ 2,759

Note 1 - The Company and Basi_2

Note 1 - The Company and Basis of Presentation (Details Textual) - USD ($)	Jul. 02, 2021	May 04, 2021	Mar. 31, 2021	Jan. 19, 2021	Jun. 09, 2020	Jun. 08, 2020	Apr. 20, 2020	Apr. 16, 2020	Apr. 15, 2020	Feb. 28, 2021	Sep. 30, 2020	Aug. 31, 2020	Jun. 30, 2020	May 31, 2020	Feb. 29, 2020	Mar. 31, 2021	Sep. 30, 2021	Dec. 31, 2021	Dec. 31, 2020		Jun. 23, 2021	May 03, 2021	Jan. 31, 2021	Jan. 18, 2021	Dec. 16, 2020	Dec. 15, 2020	Dec. 31, 2019
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)																		$ 2,720	$ 2,720
Fair Value Adjustment of Warrants																		$ 373,000	$ 1,838,000
Proceeds from Warrant Exercises																		$ 179,000	$ 8,407,000
Stock Issued During Period, Shares, Warrant Exercises (in shares)																		52,760	1,209,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)																		2	2
Proceeds from Issuance of Common Stock																		$ 25,122,000	$ 0
Payments of Warrant Issuance Costs							$ 334,000											0	334,000
Retained Earnings (Accumulated Deficit), Ending Balance																		(241,853,000)	(219,826,000)	[1]
Cash and Cash Equivalents, at Carrying Value, Ending Balance																		19,162,000	6,523,000	[1]
Working Capital																		17,705,000
Net Cash Provided by (Used in) Financing Activities, Total																		25,973,000	9,230,000
Net Cash Provided by (Used in) Operating Activities, Total																		$ (12,878,000)	$ (15,234,000)
Series B Preferred Stock [Member]
Proceeds from Warrant Exercises										$ 136,000
Stock Issued During Period, Shares, Warrant Exercises (in shares)										40,000
Preferred Stock, Shares Outstanding, Ending Balance (in shares)																		40,504	35,819
Convertible Preferred Stock, Shares Issued upon Conversion (in shares)																		2,647,320	2,341,111
Preferred Stock, Shares Authorized (in shares)																		10,000,000	10,000,000
Preferred Stock, Par or Stated Value Per Share (in dollars per share)																		$ 0.0001	$ 0.0001
January 2021 Offering Warrants [Member]
Proceeds from Warrant Exercises										$ 43,000
Stock Issued During Period, Shares, Warrant Exercises (in shares)										12,760
Series B Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)																		285,632
Series A-2 Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)																		392,830
Series B-2 Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)																		20,380
Series C Preferred Stock [Member]
Preferred Stock, Shares Outstanding, Ending Balance (in shares)			0													0		0	0				0
Convertible Preferred Stock, Shares Issued upon Conversion (in shares)																		1
Preferred Stock, Shares Authorized (in shares)																		10,000,000	10,000,000
Preferred Stock, Par or Stated Value Per Share (in dollars per share)																		$ 0.0001	$ 0.0001
Series A Preferred Stock [Member]
Preferred Stock, Shares Outstanding, Ending Balance (in shares)																		0							0
Convertible Preferred Stock, Shares Issued upon Conversion (in shares)																		1
Preferred Stock, Shares Authorized (in shares)																										547,345
Preferred Stock, Par or Stated Value Per Share (in dollars per share)																										$ 0.0001
Series A and Series B Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)				$ 3.40					$ 6.10																		$ 15.50
Fair Value Adjustment of Warrants				$ 287,000					$ 1,838,000
Proceeds from Warrant Exercises								$ 3,089,000
Series B Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)				$ 3.40																				$ 6.10
Proceeds from Warrant Exercises										$ 136,000	$ 9,000	$ 2,324,000	$ 31,000		$ 70,000
Stock Issued During Period, Shares, Warrant Exercises (in shares)								24,279		40,000	1,500	380,913	5,070		4,548
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)																		285,632
Series A-2 and Series B-2 Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)				$ 3.40			$ 6.371																	$ 6.371
Fair Value Adjustment of Warrants				$ 287,000
Warrants and Rights Outstanding, Term (Year)							5 years
Payments of Warrant Issuance Costs							$ 334,000
Series B, A-2 and B-2 Common Stock Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 2.817																				$ 3.40
Fair Value Adjustment of Warrants		$ 86,000
Warrants Issued in Connection with Class A Units [Member] | Class A Units [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)				$ 3.40
Warrants Per Unit (in shares)				1
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)				1
Warrants and Rights Outstanding, Term (Year)				5 years
Warrants Issued in Connection with Class B Units [Member] | Class B Units [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)				$ 3.40
Warrants Per Unit (in shares)				1
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)				1
Warrants and Rights Outstanding, Term (Year)				5 years
Warrants Issued in Connection with January 2021 Offering [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)																							$ 3.40
Proceeds from Warrant Exercises																$ 43,000
Stock Issued During Period, Shares, Warrant Exercises (in shares)																12,760
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)			8,104,880	8,117,640												8,104,880		8,104,880					8,117,640
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)																							1
Series A Warrants [Member]
Proceeds from Warrant Exercises												$ 681,000	$ 17,000	$ 2,000	$ 1,591,000
Stock Issued During Period, Shares, Warrant Exercises (in shares)								482,059				111,704	2,761	410	102,626
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)																		0
Series A-2 Warrants [Member]
Proceeds from Warrant Exercises												$ 568,000
Stock Issued During Period, Shares, Warrant Exercises (in shares)												89,230					392,830
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)							482,059											392,830
Series B-2 Warrants [Member]
Proceeds from Warrant Exercises												$ 25,000
Stock Issued During Period, Shares, Warrant Exercises (in shares)												3,899					20,380
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)							24,279											20,380
Universal Shelf Registration Statement [Member]
Universal Shelf Registration Statement, Proposed Maximum Securities Offering	$ 75,000,000
Universal Shelf Registration Statement, Maximum Capacity																		$ 75,000,000
Stock Issued During Period, Shares, New Issues (in shares)																		0
Proceeds from Issuance or Sale of Equity, Total																		$ 0
Purchase Agreement with LPC [Member]
Stock Issued During Period, Shares, New Issues (in shares)		250,000			52,500
Shares Issued, Price Per Share (in dollars per share)		$ 2.817			$ 6.50
Maximum Amount of Shares Issuable						$ 10,000,000
Stock Purchase Agreement Duration Period (Month)						30 months
Stock Purchase Agreement, Maximum Issuable Shares (in shares)						301,762
Stock Purchase Agreement, Maximum Issuable Shares, Percent of Outstanding Stock						19.99%
Stock Purchase Agreement, Share Price Covenant Trigger (in dollars per share)						$ 6.46
Proceeds from Issuance of Common Stock		$ 704,000			$ 341,000
Payments of Stock Issuance Costs					$ 494,000													70,000	$ 494,000
Equity Facility, Remaining Financing Commitment																		$ 9,000,000
January 2021 Offering [Member]
Shares Issued, Price Per Share (in dollars per share)				$ 3.40
Proceeds from Issuance or Sale of Equity, Total				$ 27,600,000
Proceeds from Issuance or Sale of Equity, Net of Issuance Costs				$ 25,122,000
January 2021 Offering [Member] | Class A Units [Member]
Shares Issued, Price Per Share (in dollars per share)				$ 3.40
Units Issued, Shares (in shares)				4,607,940
Common Shares Per Unit (in shares)				1
Warrants Per Unit (in shares)				1
January 2021 Offering [Member] | Class B Units [Member]
Shares Issued, Price Per Share (in dollars per share)				$ 3.40
Units Issued, Shares (in shares)				2,450,880
Common Shares Per Unit (in shares)				1
Warrants Per Unit (in shares)				1
Series C Convertible Preferred Stock Per Unit (in shares)				1
January 2021 Offering [Member] | Series C Preferred Stock [Member]
Stock Issued During Period, Shares, New Issues (in shares)				2,450,880
Convertible Preferred Stock, Shares Issued upon Conversion (in shares)			1													1
Over-Allotment Option [Member]
Stock Issued During Period, Shares, New Issues (in shares)				1,058,820
Over-Allotment Option [Member] | Warrants Issued in Connection with January 2021 Offering [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)				1,058,820
First Amendment to the LPC Purchase Agreement [Member]
Stock Issued During Period, Shares, New Issues (in shares)		250,000
Shares Issued, Price Per Share (in dollars per share)		$ 2.817
Stock Purchase Agreement, Maximum Issuable Shares (in shares)			2,068,342													2,068,342
Stock Purchase Agreement, Maximum Issuable Shares, Percent of Outstanding Stock			19.99%													19.99%					20.00%
Stock Purchase Agreement, Share Price Covenant Trigger (in dollars per share)			$ 2.99													$ 2.99
Proceeds from Issuance of Common Stock		$ 704,000
Payments of Stock Issuance Costs			$ 70,000
[1]	The condensed consolidated balance sheet as of December 31, 2020 has been derived from the audited consolidated financial statements as of that date.

Note 2 - Summary of Significa_3

Note 2 - Summary of Significant Accounting Policies (Details Textual)	Dec. 01, 2020USD ($)shares	Dec. 31, 2021USD ($)$ / sharesshares	Dec. 31, 2020USD ($)shares	Mar. 31, 2021shares	Jan. 31, 2021shares	Dec. 16, 2020shares
Common Stock, Shares Authorized (in shares) | shares	75,000,000	75,000,000	75,000,000
Payments for Fractional Shares of Reverse Stock Split	$ 0
Reverse Stock Split, Rounding Adjustment (in shares) | shares	5,931
Number of Financial Institutions		1
Accounts Receivable, Allowance for Credit Loss, Ending Balance		$ 66,000	$ 124,000
Accounts Receivable, Allowance for Credit Loss, Writeoff		183,000	736,000
Inventory, Finished Goods, Net of Reserves		979,000	2,818,000
Inventory, Raw Materials, Net of Reserves		493,000	436,000
Impairment, Long-Lived Asset, Held-for-Use, Total		0
Revenue from Contract with Customer, Excluding Assessed Tax, Total		6,426,000	5,479,000
Contract with Customer, Asset, after Allowance for Credit Loss, Total		0	0
Contract with Customer, Liability, Total		7,000	17,000
Capitalized Contract Cost, Net, Total		84,000	132,000
Capitalized Contract Cost, Amortization		66,000	417,000
Capitalized Contract Cost, Impairment Loss		0
Equity Method Investment, Other than Temporary Impairment		$ 0	$ 0
Series A Preferred Stock [Member]
Convertible Preferred Stock, Shares Issued upon Conversion (in shares) | shares		1
Preferred Stock, Shares Outstanding, Ending Balance (in shares) | shares		0				0
Series B Preferred Stock [Member]
Convertible Preferred Stock, Shares Issued upon Conversion (in shares) | shares		2,647,320	2,341,111
Preferred Stock, Shares Outstanding, Ending Balance (in shares) | shares		40,504	35,819
Conversion of Stock Exchange Ratio		65.36
Preferred Stock, Liquidation Preference Per Share (in dollars per share) | $ / shares		$ 1,000
Conversion of Stock, Conversion Rate (in dollars per share) | $ / shares		$ 15.30
Series C Preferred Stock [Member]
Convertible Preferred Stock, Shares Issued upon Conversion (in shares) | shares		1
Preferred Stock, Shares Outstanding, Ending Balance (in shares) | shares		0	0	0	0
Conversion of Stock Exchange Ratio		1
Rental [Member]
Revenue from Contract with Customer, Excluding Assessed Tax, Total		$ 1,214,000	$ 1,337,000
Contract with Customer, Liability, Current		452,000	345,000
Contract with Customer, Liability, Revenue Recognized		318,000	594,000
Marketing Programs [Member]
Contract with Customer, Liability, Total		$ 7,000	$ 17,000
Minimum [Member]
Property, Plant and Equipment, Useful Life (Year)		3 years
Warranty Period (Year)		1 year
Minimum [Member] | Viveve Systems [Member]
Lessor, Operating Lease, Term of Contract (Month)		6 months
Maximum [Member]
Property, Plant and Equipment, Useful Life (Year)		7 years
Warranty Period (Year)		3 years
Maximum [Member] | Viveve Systems [Member]
Lessor, Operating Lease, Term of Contract (Month)		12 months
Viveve Systems [Member]
Property, Plant and Equipment, Useful Life (Year)		5 years
Customer Concentration Risk [Member] | Revenue Benchmark [Member]
Concentration Risk, Number of Customers		1	1
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | One Customer [Member]
Concentration Risk, Percentage		30.00%	36.00%
Customer Concentration Risk [Member] | Accounts Receivable [Member]
Concentration Risk, Number of Customers		1	1
Customer Concentration Risk [Member] | Accounts Receivable [Member] | One Customer [Member]
Concentration Risk, Number of Customers		10
Concentration Risk, Percentage			37.00%
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio	10

Note 2 - Summary of Significa_4

Note 2 - Summary of Significant Accounting Policies - Customer Contract Liabilities (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Customer contract liabilities	$ 7,000	$ 17,000
Change in customer contract liabilities		(10,000)
Marketing Programs [Member]
Customer contract liabilities	7,000	$ 17,000
Change in customer contract liabilities	$ (10,000)

Note 2 - Summary of Significa_5

Note 2 - Summary of Significant Accounting Policies - Revenue From Unaffiliated Customers by Geographic Area (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Revenue	$ 6,426	$ 5,479
UNITED STATES
Revenue	3,701	2,537
Asia Pacific [Member]
Revenue	2,647	2,732
CANADA
Revenue	66	110
Europe And Middle East [Member]
Revenue	12	86
Latin America [Member]
Revenue	$ 0	$ 14

Note 2 - Summary of Significa_6

Note 2 - Summary of Significant Accounting Policies - Antidilutive Securities (Details) - shares		12 Months Ended
		Dec. 31, 2021	Dec. 31, 2020
Series A Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share (in shares)	[1]	0	0
Series B Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share (in shares)	[2]	2,647,320	2,341,111
Series C Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share (in shares)	[3]	0	0
Common Stock Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share (in shares)		9,793,599	1,728,725
Share-based Payment Arrangement, Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share (in shares)		3,173,103	986,399
Restricted Stock Units (RSUs) [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share (in shares)		674,000	0
Restricted Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share (in shares)		228	234
[1]	Each share of Series A convertible preferred stock was convertible at any time at the holder's option into one share of common stock. In December 2020, the Company filed a Certificate of Elimination with the Delaware Secretary of State with respect to the authorized shares of Series A convertible preferred stock. As of December 31, 2021, all Series A convertible preferred stock had been converted into common stock and there were no remaining shares outstanding.
[2]	As of December 31, 2021 and 2020, a total of 40,504 and 35,819 shares of Series B convertible preferred stock were outstanding and convertible into 2,647,320 and 2,341,111 shares of common stock, respectively. Each share of Series B convertible preferred stock is convertible at the holder's option into shares of common stock at a conversion ratio of 1-for-65.36 per share determined by dividing the Series B liquidation amount of $1,000 per share by the Series B conversion price of $15.30 per share. However, under the terms of the Series B Preferred Stock and Warrant Purchase Agreement, as amended, CRG will not convert the Series B preferred stock or exercise the CRG warrants until the Company’s stockholders act to authorize additional number of shares of common stock sufficient to cover the conversion shares.
[3]	Agreement, as amended, CRG will not convert the Series B preferred stock or exercise the CRG warrants until the Company’s stockholders act to authorize additional number of shares of common stock sufficient to cover the conversion shares. Each share of Series C preferred stock is convertible at any time at the holder’s option into one share of common stock. As of December 31, 2021, all Series C convertible preferred stock had been converted into common stock and there are no remaining shares of Series C convertible preferred stock outstanding.

Note 4 - Property and Equipme_3

Note 4 - Property and Equipment, Net (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Depreciation, Total	$ 1,123,000	$ 1,295,000

Note 4 - Property and Equipme_4

Note 4 - Property and Equipment, Net - Equipment, Furniture, and Leasehold Improvements (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Property and equipment, gross	$ 4,304	$ 5,698
Less: Accumulated depreciation and amortization	(2,750)	(2,939)
Property and equipment, net	$ 1,554	2,759	[1]
Equipment [Member]
Property, Plant and Equipment, Useful Life (Year)	5 years
Property and equipment, gross	$ 2,628	3,111
Rental Program Equipment [Member]
Property, Plant and Equipment, Useful Life (Year)	5 years
Property and equipment, gross	$ 1,118	1,812
Computer Equipment [Member]
Property, Plant and Equipment, Useful Life (Year)	3 years
Property and equipment, gross	$ 157	242
Leasehold Improvements [Member]
Property, Plant and Equipment, Useful Life (Year)	3 years
Property and equipment, gross	$ 122	122
Furniture and Fixtures [Member]
Property, Plant and Equipment, Useful Life (Year)	7 years
Property and equipment, gross	$ 244	386
Software [Member]
Property, Plant and Equipment, Useful Life (Year)	3 years
Property and equipment, gross	$ 35	$ 25
[1]	The condensed consolidated balance sheet as of December 31, 2020 has been derived from the audited consolidated financial statements as of that date.

Note 5 - Investment in Limite_2

Note 5 - Investment in Limited Liability Company (Details Textual)	Aug. 08, 2017USD ($)	Dec. 31, 2021USD ($)	Dec. 31, 2020USD ($)	Dec. 13, 2021USD ($)
Income (Loss) from Equity Method Investments, Total		$ (256,000)	$ (383,000)
InControl Medical [Member]
Income (Loss) from Equity Method Investments, Total		$ 256,000	$ 383,000
InControl Medical [Member] | Membership Unit Subscription Agreement [Member]
Payments to Acquire Equity Method Investments	$ 2,500,000
Equity Method Investment, Ownership Percentage	7.00%
Unrecorded Unconditional Purchase Obligation, Period Quantity Purchased		140	485
Unrecorded Unconditional Purchase Obligation, Purchases		$ 17,000	$ 51,000
Payments for Purchase of Products		$ 17,000	52,000
Accounts Payable, Related Parties, Current			$ 0	$ 0

Note 6 - Accrued Liabilities -

Note 6 - Accrued Liabilities - Accrued Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Accrued bonuses	$ 1,209	$ 744
Accrued payroll and other related expenses	495	473
Deferred revenue - subscription rental program	448	345
Accrued clinical trial costs	337	91
Accrued professional fees	120	290
Other accruals	219	341
Total accrued liabilities	3,053	2,416	[1]
Accrued Liabilities [Member]
Current operating lease liabilities	$ 225	$ 132
[1]	The condensed consolidated balance sheet as of December 31, 2020 has been derived from the audited consolidated financial statements as of that date.

Note 7 - Note Payable (Details

Note 7 - Note Payable (Details Textual) - USD ($)	Nov. 12, 2019	Dec. 29, 2017	May 22, 2017	Dec. 31, 2021	Dec. 31, 2020
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)				2	2
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)				$ 2,720	$ 2,720
Notes Payable, Noncurrent, Total				$ 5,124,000	$ 4,518,000	[1]
Series B Convertible Preferred Stock Into Common Stock [Member] | Minimum [Member]
Conversion of Stock, Conversion Rate (in dollars per share)	$ 15.30
Series B Convertible Preferred Stock Into Common Stock [Member] | Maximum [Member]
Conversion of Stock, Conversion Rate (in dollars per share)	$ 18.36
Conversion of Term Loan with CRG Into Stock and Warrants [Member]
Debt Conversion, Original Debt, Amount	$ 28,981,000
Debt Conversion, Converted Instrument, Amount	$ 31,300,000
Conversion of Term Loan with CRG Into Series B Convertible Preferred Stock [Member]
Debt Conversion, Converted Instrument, Shares Issued (in shares)	31,300
May 2017 Issuance Related to 2017 Loan Agreement [Member]
Warrants and Rights Outstanding, Term (Year)			10 years
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)			223
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)			$ 9,500
Warrants Issued Upon Conversion of Term Loan with CRG [Member]
Warrants and Rights Outstanding, Term (Year)	5 years
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	989,379
Class of Warrants and Rights Outstanding, Exercise Price Percentage of Conversion Rate	120.00%
The 2017 Loan Agreement [Member]
Notes Payable, Noncurrent, Total				5,124,000
The 2017 Loan Agreement [Member] | CRG LP [Member]
Debt Instrument, Face Amount			$ 20,000,000
Debt Agreement, Covenant, Additional Funding			10,000,000
Debt Agreement, Maximum Borrowing Capacity			$ 30,000,000
Proceeds from Lines of Credit, Total		$ 10,000,000
Debt Instrument, Term (Year)			6 years
Debt instrument, Interest Only Payment, Period (Year)			4 years
Debt Instrument, Interest Rate, Stated Percentage			12.50%
Debt Instrument, Interest Rate, Stated Percentage Deferred During Interest-only Period			4.00%
Debt Instrument, Prepayment Fee, Percentage			5.00%
Debt Instrument, Back-end Facility Fee Percentage of Principal	25.00%		5.00%
Paid-in-Kind Interest				602,000	532,000
Notes Payable, Noncurrent, Total				$ 5,124,000	$ 4,518,000
[1]	The condensed consolidated balance sheet as of December 31, 2020 has been derived from the audited consolidated financial statements as of that date.

Note 7 - Note Payable - Summary

Note 7 - Note Payable - Summary of Note Payable (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020	[1]
Less: Unamortized debt discount	$ (5,000)
Note payable, noncurrent portion	5,124,000	$ 4,518,000
The 2017 Loan Agreement [Member]
2022	0
2023	5,992,000
Total Payments	5,992,000
Less: Amount representing interest	(863,000)
Present value of obligations	5,129,000
Less: Unamortized debt discount	(5,000)
Note payable, noncurrent portion	$ 5,124,000
[1]	The condensed consolidated balance sheet as of December 31, 2020 has been derived from the audited consolidated financial statements as of that date.

Note 8 - Paycheck Protection _2

Note 8 - Paycheck Protection Program Loan (Details Textual) - USD ($)	Apr. 24, 2020	Dec. 31, 2021	Dec. 31, 2021	Dec. 31, 2020
Proceeds from Issuance of Unsecured Debt			$ 0	$ 1,343,000
Gain (Loss) on Extinguishment of Debt, Total			$ 1,358,000	$ 0
Paycheck Protection Program CARES Act [Member]
Proceeds from Issuance of Unsecured Debt	$ 1,343,000
Gain (Loss) on Extinguishment of Debt, Total		$ 1,358,000

Note 9 - Leases (Details Textua

Note 9 - Leases (Details Textual)	1 Months Ended				12 Months Ended
	Jun. 30, 2021USD ($)	Mar. 31, 2021USD ($)	Oct. 31, 2020USD ($)	Sep. 30, 2018USD ($)	Dec. 31, 2021USD ($)	Dec. 31, 2020USD ($)	Dec. 01, 2019	Feb. 01, 2017USD ($)ft²
Operating Lease, Expense					$ 280,000	$ 300,000
Operating Lease, Weighted Average Remaining Lease Term (Month)					27 months
Operating Lease, Weighted Average Discount Rate, Percent					12.50%
Operating Lease, Property Plant and Equipment, Amount					$ 464,000
Sublease Agreement for Relocation of Headquarters [Member]
Area of Real Estate Property (Square Foot) | ft²								12,400
Lessee, Operating Lease, Renewal Term (Year)		34 months					1 year
Operating Leases, Monthly Rent Per Rentable Square Foot During First Year								20.50
Operating Leases, Monthly Rent Per Rentable Square Foot During Second Year								21.12
Operating Leases, Monthly Rent Per Rentable Square Foot During Third Year								21.75
Security Deposit								$ 22,000
Operating Leases, Allowance for Certain Improvements								$ 88,000
Lessee, Operating Lease, Rent Abatement	$ 19,000
Sublease Agreement for Relocation of Headquarters First Year Extension [Member]
Lessee, Operating Lease, Monthly Gross Rent		$ 21,028
Sublease Agreement for Relocation of Headquarters Second Year Extension [Member]
Lessee, Operating Lease, Monthly Gross Rent		21,643
Sublease Agreement for Relocation of Headquarters Third Year Extension [Member]
Lessee, Operating Lease, Monthly Gross Rent		$ 22,258
Noncancelable Operating Lease Agreement for Office Equipment [Member]
Lessee, Operating Lease, Term of Contract (Month)			36 months	36 months
Operating Leases, Monthly Payment			$ 2,000	$ 3,000
Leases of Viveve Systems [Member]
Lessor, Operating Lease, Depreciation on Leased Assets					$ 325,000	$ 462,000

Note 9 - Leases - Lease Assets

Note 9 - Leases - Lease Assets and Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Other Assets [Member]
Operating lease right-of-use assets	$ 534	$ 130
Accrued Liabilities [Member]
Current operating lease liabilities	225	132
Other Noncurrent Liabilities [Member]
Noncurrent operating lease liabilities	327	0
Accrued Liabilities and Other Noncurrent Liabilities [Member]
Operating Lease, Liability, Total	$ 552	$ 132

Note 9 - Leases - Maturity of O

Note 9 - Leases - Maturity of Operating Lease Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
2022	$ 282
2023	287
2024	67
Total lease payments	636
Less: Amount representing interest	(84)
Accrued Liabilities and Other Noncurrent Liabilities [Member]
Present value of lease liabilities	$ 552	$ 132

Note 9 - Leases - Minimum Futur

Note 9 - Leases - Minimum Future Rentals (Details) $ in Thousands	Dec. 31, 2021USD ($)
2022	$ 448
2023	4
Total	$ 452

Note 11 - Preferred Stock (Deta

Note 11 - Preferred Stock (Details Textual)	Jan. 19, 2021shares	Nov. 26, 2019	Nov. 12, 2019shares	Dec. 31, 2021USD ($)$ / sharesshares	Dec. 31, 2020USD ($)shares	Dec. 31, 2021USD ($)$ / sharesshares	Mar. 31, 2021shares	Jan. 31, 2021shares	Dec. 16, 2020shares	Dec. 15, 2020shares
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)				2	2	2
Warrants Issued Upon Conversion of Term Loan with CRG [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)			989,379
Conversion of Term Loan with CRG Into Series B Convertible Preferred Stock [Member]
Debt Conversion, Converted Instrument, Shares Issued (in shares)			31,300
Series A Preferred Stock [Member]
Preferred Stock, Shares Outstanding, Ending Balance (in shares)				0		0			0
Preferred Stock, Shares Authorized (in shares)										547,345
Convertible Preferred Stock, Shares Issued upon Conversion (in shares)				1		1
Series B Preferred Stock [Member]
Preferred Stock, Shares Outstanding, Ending Balance (in shares)				40,504	35,819	40,504
Preferred Stock, Shares Authorized (in shares)				10,000,000	10,000,000	10,000,000
Preferred Stock, Dividend Rate, Percentage		12.50%
Preferred Stock Dividends, Shares (in shares)				4,685	4,141	9,204
Dividends, Preferred Stock, Cash | $				$ 6,400	$ 8,000	$ 17,000
Convertible Preferred Stock, Shares Issued upon Conversion (in shares)				2,647,320	2,341,111	2,647,320
Conversion of Stock Exchange Ratio				65.36
Preferred Stock, Liquidation Preference Per Share (in dollars per share) | $ / shares				$ 1,000		$ 1,000
Conversion of Stock, Conversion Rate (in dollars per share) | $ / shares				$ 15.30		$ 15.30
Series C Preferred Stock [Member]
Preferred Stock, Shares Outstanding, Ending Balance (in shares)				0	0	0	0	0
Preferred Stock, Shares Authorized (in shares)				10,000,000	10,000,000	10,000,000
Convertible Preferred Stock, Shares Issued upon Conversion (in shares)				1		1
Conversion of Stock Exchange Ratio				1
Series C Preferred Stock [Member] | January 2021 Offering [Member]
Convertible Preferred Stock, Shares Issued upon Conversion (in shares)							1
Stock Issued During Period, Shares, New Issues (in shares)	2,450,880

Note 12 - Common Stock (Details

Note 12 - Common Stock (Details Textual)	May 04, 2021USD ($)$ / sharesshares	Mar. 31, 2021USD ($)$ / sharesshares	Jan. 19, 2021USD ($)$ / sharesshares	Jun. 09, 2020USD ($)$ / sharesshares	Jun. 08, 2020USD ($)$ / sharesshares	Apr. 20, 2020USD ($)$ / sharesshares	Apr. 16, 2020USD ($)shares	Apr. 15, 2020USD ($)$ / shares	Mar. 31, 2021USD ($)$ / sharesshares	Feb. 28, 2021USD ($)shares	Sep. 30, 2020USD ($)shares	Aug. 31, 2020USD ($)shares	Jun. 30, 2020USD ($)shares	May 31, 2020USD ($)shares	Mar. 31, 2020USD ($)shares	Feb. 29, 2020USD ($)shares	Mar. 31, 2021USD ($)$ / sharesshares	Sep. 30, 2021shares	Dec. 31, 2021USD ($)$ / sharesshares	Dec. 31, 2020USD ($)$ / sharesshares	Jun. 23, 2021	Jan. 31, 2021$ / sharesshares	Jan. 18, 2021$ / shares	Dec. 31, 2019$ / shares	Nov. 12, 2019USD ($)$ / sharesshares	May 22, 2017$ / sharesshares
Proceeds from Issuance of Common Stock | $																			$ 25,122,000	$ 0
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares																			$ 2,720	$ 2,720
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)																			2	2
Stock Issued During Period, Shares, Warrant Exercises (in shares)																			52,760	1,209,000
Proceeds from Warrant Exercises | $																			$ 179,000	$ 8,407,000
Stock Issued During Period, Share, Restricted Common Shares (in shares)											4,709		3,453		2,832				0
Stock Issued During Period, Value, Restricted Common Shares | $											$ 25,000		$ 25,000		$ 24,000					74,000
Amortization of Debt Discount (Premium) | $																			$ 4,000	3,000
Debt Instrument, Unamortized Discount, Total | $																			5,000
Fair Value Adjustment of Warrants | $																			373,000	1,838,000
Payments of Warrant Issuance Costs | $						$ 334,000													$ 0	$ 334,000
Class of Warrant or Right Number of Securities Called by Warrants or Rights Cancelled In Period (in shares)																			0	0
Class Of Warrant Or Right, Number Of Securities Called By Warrants Or Rights Expired In Period (in shares)																			6	42,404
Series B Convertible Preferred Stock Into Common Stock [Member] | Minimum [Member]
Conversion of Stock, Conversion Rate (in dollars per share) | $ / shares																									$ 15.30
Series B Convertible Preferred Stock Into Common Stock [Member] | Maximum [Member]
Conversion of Stock, Conversion Rate (in dollars per share) | $ / shares																									$ 18.36
Series C Preferred Stock [Member]
Preferred Stock, Shares Outstanding, Ending Balance (in shares)		0							0								0		0	0		0
Warrants Issued in Connection with January 2021 Offering [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)																						1
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares																						$ 3.40
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		8,104,880	8,117,640						8,104,880								8,104,880		8,104,880			8,117,640
Stock Issued During Period, Shares, Warrant Exercises (in shares)																	12,760
Proceeds from Warrant Exercises | $																	$ 43,000
May 2017 Issuance Related to 2017 Loan Agreement [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares																										$ 9,500
Warrants and Rights Outstanding, Term (Year)																										10 years
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)																										223
Warrants Issued Upon Conversion of Term Loan with CRG [Member]
Warrants and Rights Outstanding, Term (Year)																									5 years
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)																									989,379
Class of Warrants or Rights, Outstanding, Percentage of Common Stock																									15.00%
Class of Warrants and Rights Outstanding, Exercise Price Percentage of Conversion Rate																									120.00%
Warrants and Rights Outstanding | $																									$ 3,502,000
Warrants Issued Upon Conversion of Term Loan with CRG [Member] | Measurement Input, Expected Dividend Rate [Member]
Warrants and Rights Outstanding, Measurement Input																									0
Warrants Issued Upon Conversion of Term Loan with CRG [Member] | Measurement Input, Price Volatility [Member]
Warrants and Rights Outstanding, Measurement Input																									68.8
Warrants Issued Upon Conversion of Term Loan with CRG [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrants and Rights Outstanding, Measurement Input																									1.58
Warrants Issued Upon Conversion of Term Loan with CRG [Member] | Measurement Input, Expected Term [Member]
Warrants and Rights Outstanding, Measurement Input																									5
Series A Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)																			0
Stock Issued During Period, Shares, Warrant Exercises (in shares)							482,059					111,704	2,761	410		102,626
Proceeds from Warrant Exercises | $												$ 681,000	$ 17,000	$ 2,000		$ 1,591,000
Series B Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares			$ 3.40																				$ 6.10
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)																			285,632
Stock Issued During Period, Shares, Warrant Exercises (in shares)							24,279			40,000	1,500	380,913	5,070			4,548
Proceeds from Warrant Exercises | $										$ 136,000	$ 9,000	$ 2,324,000	$ 31,000			$ 70,000
Series A and Series B Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares			$ 3.40					$ 6.10																$ 15.50
Proceeds from Warrant Exercises | $							$ 3,089,000
Fair Value Adjustment of Warrants | $			$ 287,000					$ 1,838,000
Series A-2 Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)						482,059													392,830
Stock Issued During Period, Shares, Warrant Exercises (in shares)												89,230						392,830
Proceeds from Warrant Exercises | $												$ 568,000
Series B-2 Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)						24,279													20,380
Stock Issued During Period, Shares, Warrant Exercises (in shares)												3,899						20,380
Proceeds from Warrant Exercises | $												$ 25,000
Series A-2 and Series B-2 Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares			$ 3.40			$ 6.371																	$ 6.371
Warrants and Rights Outstanding, Term (Year)						5 years
Fair Value Adjustment of Warrants | $			$ 287,000
Class of Warrant or Right, Outstanding (in shares)						1,838,000
Payments of Warrant Issuance Costs | $						$ 334,000
Series A-2 and Series B-2 Warrants [Member] | Measurement Input, Expected Dividend Rate [Member]
Warrants and Rights Outstanding, Measurement Input						0
Series A-2 and Series B-2 Warrants [Member] | Measurement Input, Price Volatility [Member]
Warrants and Rights Outstanding, Measurement Input						84.1
Series A-2 and Series B-2 Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrants and Rights Outstanding, Measurement Input						0.35
Series A-2 and Series B-2 Warrants [Member] | Measurement Input, Expected Term [Member]
Warrants and Rights Outstanding, Measurement Input						5
Series B, A-2 and B-2 Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares	$ 2.817
Fair Value Adjustment of Warrants | $	$ 86,000
January 2021 Offering Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)																			8,104,880
Stock Issued During Period, Shares, Warrant Exercises (in shares)									4,000	8,760
Proceeds from Warrant Exercises | $									$ 13,000	$ 30,000
Class A Units [Member] | Warrants Issued in Connection with Class A Units [Member]
Warrants Per Unit (in shares)			1
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)			1
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares			$ 3.40
Warrants and Rights Outstanding, Term (Year)			5 years
Class B Units [Member] | Warrants Issued in Connection with Class B Units [Member]
Warrants Per Unit (in shares)			1
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)			1
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares			$ 3.40
Warrants and Rights Outstanding, Term (Year)			5 years
Purchase Agreement with LPC [Member]
Maximum Amount of Shares Issuable | $					$ 10,000,000
Stock Purchase Agreement Duration Period (Month)					30 months
Stock Purchase Agreement, Maximum Issuable Shares (in shares)					301,762
Stock Purchase Agreement, Maximum Issuable Shares, Percent of Outstanding Stock					19.99%
Stock Purchase Agreement, Share Price Covenant Trigger (in dollars per share) | $ / shares					$ 6.46
Stock Issued During Period, Shares, New Issues (in shares)	250,000			52,500
Shares Issued, Price Per Share (in dollars per share) | $ / shares	$ 2.817			$ 6.50
Proceeds from Issuance of Common Stock | $	$ 704,000			$ 341,000
Payments of Stock Issuance Costs | $				494,000															$ 70,000	$ 494,000
Equity Facility, Remaining Financing Commitment | $																			$ 9,000,000
Purchase Agreement with LPC [Member] | Commitment Fee [Member]
Payments of Stock Issuance Costs | $				$ 325,000
First Amendment to the LPC Purchase Agreement [Member]
Stock Purchase Agreement, Maximum Issuable Shares (in shares)		2,068,342							2,068,342								2,068,342
Stock Purchase Agreement, Maximum Issuable Shares, Percent of Outstanding Stock		19.99%							19.99%								19.99%				20.00%
Stock Purchase Agreement, Share Price Covenant Trigger (in dollars per share) | $ / shares		$ 2.99							$ 2.99								$ 2.99
Stock Issued During Period, Shares, New Issues (in shares)	250,000
Shares Issued, Price Per Share (in dollars per share) | $ / shares	$ 2.817
Proceeds from Issuance of Common Stock | $	$ 704,000
Payments of Stock Issuance Costs | $		$ 70,000
January 2021 Offering [Member]
Shares Issued, Price Per Share (in dollars per share) | $ / shares			$ 3.40
Proceeds from Issuance or Sale of Equity, Total | $			$ 27,600,000
Proceeds from Issuance or Sale of Equity, Net of Issuance Costs | $			$ 25,122,000
January 2021 Offering [Member] | Series C Preferred Stock [Member]
Stock Issued During Period, Shares, New Issues (in shares)			2,450,880
January 2021 Offering [Member] | Class A Units [Member]
Shares Issued, Price Per Share (in dollars per share) | $ / shares			$ 3.40
Units Issued, Shares (in shares)			4,607,940
Common Shares Per Unit (in shares)			1
Warrants Per Unit (in shares)			1
January 2021 Offering [Member] | Class B Units [Member]
Shares Issued, Price Per Share (in dollars per share) | $ / shares			$ 3.40
Units Issued, Shares (in shares)			2,450,880
Common Shares Per Unit (in shares)			1
Warrants Per Unit (in shares)			1
Over-Allotment Option [Member]
Stock Issued During Period, Shares, New Issues (in shares)			1,058,820
Over-Allotment Option [Member] | Warrants Issued in Connection with January 2021 Offering [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)			1,058,820

Note 12 - Common Stock - Summar

Note 12 - Common Stock - Summary of Outstanding Warrants (Details) - $ / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Expiration Date	Mar. 26, 2025	Mar. 26, 2025
Exercise Price (in dollars per share)	$ 2,720	$ 2,720
Shares Outstanding Under Warrants (in shares)	2	2
Warrant One [Member]
Expiration Date	Feb. 17, 2025	Feb. 17, 2025
Exercise Price (in dollars per share)	$ 4,000	$ 4,000
Shares Outstanding Under Warrants (in shares)	79	79
Warrant Two [Member]
Expiration Date	May 12, 2025	May 12, 2025
Exercise Price (in dollars per share)	$ 4,240	$ 4,240
Shares Outstanding Under Warrants (in shares)	37	37
Warrant Three [Member]
Expiration Date	Dec. 16, 2025	Dec. 16, 2025
Exercise Price (in dollars per share)	$ 5,600	$ 5,600
Shares Outstanding Under Warrants (in shares)	31	31
Warrant Four [Member]
Expiration Date	Apr. 1, 2026	Apr. 1, 2026
Exercise Price (in dollars per share)	$ 6,080	$ 6,080
Shares Outstanding Under Warrants (in shares)	25	25
Warrant Five [Member]
Expiration Date	Jun. 20, 2026	May 11, 2021
Exercise Price (in dollars per share)	$ 4,980	$ 7,740
Shares Outstanding Under Warrants (in shares)	101	6
Warrant Six [Member]
Expiration Date	May 25, 2027	Jun. 20, 2026
Exercise Price (in dollars per share)	$ 9,500	$ 4,980
Shares Outstanding Under Warrants (in shares)	223	101
Warrant Seven [Member]
Expiration Date	Nov. 26, 2024	May 25, 2027
Exercise Price (in dollars per share)	$ 18.36	$ 9,500
Shares Outstanding Under Warrants (in shares)	989,379	223
Warrant Eight [Member]
Expiration Date	Nov. 26, 2024	Nov. 26, 2024
Exercise Price (in dollars per share)	$ 2.82	$ 6.10
Shares Outstanding Under Warrants (in shares)	285,632	325,632
Warrant Nine [Member]
Expiration Date	Apr. 21, 2025	Nov. 26, 2024
Exercise Price (in dollars per share)	$ 2.82	$ 18.36
Shares Outstanding Under Warrants (in shares)	413,210	989,379
Warrant Ten [Member]
Expiration Date	Jan. 19, 2026	Apr. 21, 2025
Exercise Price (in dollars per share)	$ 3.40	$ 6.37
Shares Outstanding Under Warrants (in shares)	8,104,880	413,210
Warrant Eleven [Member]
Exercise Price (in dollars per share)
Shares Outstanding Under Warrants (in shares)	9,793,599	1,728,725

Note 12 - Common Stock - Assump

Note 12 - Common Stock - Assumptions (Details)	May 04, 2021	May 03, 2021	Jan. 19, 2021	Jan. 18, 2021	Apr. 20, 2020	Apr. 15, 2020	Apr. 14, 2020
Measurement Input, Expected Term [Member] | Series A-2 and Series B-2 Warrants [Member]
Warrants and Rights Outstanding, Measurement Input					5
Measurement Input, Price Volatility [Member] | Series A-2 and Series B-2 Warrants [Member]
Warrants and Rights Outstanding, Measurement Input					84.1
Measurement Input, Risk Free Interest Rate [Member] | Series A-2 and Series B-2 Warrants [Member]
Warrants and Rights Outstanding, Measurement Input					0.35
Measurement Input, Expected Dividend Rate [Member] | Series A-2 and Series B-2 Warrants [Member]
Warrants and Rights Outstanding, Measurement Input					0
Warrant [Member] | Measurement Input, Exercise Price [Member]
Warrants and Rights Outstanding, Measurement Input						6.10	15.50
Warrant [Member] | Measurement Input, Exercise Price [Member] | Series B Warrants [Member]
Warrants and Rights Outstanding, Measurement Input			3.40	6.10
Warrant [Member] | Measurement Input, Exercise Price [Member] | Series A-2 and Series B-2 Warrants [Member]
Warrants and Rights Outstanding, Measurement Input			3.40	6.37
Warrant [Member] | Measurement Input, Exercise Price [Member] | Series B, A-2 and B-2 Warrants [Member]
Warrants and Rights Outstanding, Measurement Input	2.82	3.40
Warrant [Member] | Measurement Input, Share Price [Member]
Warrants and Rights Outstanding, Measurement Input						6.30	6.30
Warrant [Member] | Measurement Input, Share Price [Member] | Series B Warrants [Member]
Warrants and Rights Outstanding, Measurement Input			3.19	3.19
Warrant [Member] | Measurement Input, Share Price [Member] | Series A-2 and Series B-2 Warrants [Member]
Warrants and Rights Outstanding, Measurement Input			3.19	3.19
Warrant [Member] | Measurement Input, Share Price [Member] | Series B, A-2 and B-2 Warrants [Member]
Warrants and Rights Outstanding, Measurement Input	3.01	3.01
Warrant [Member] | Measurement Input, Expected Term [Member]
Warrants and Rights Outstanding, Measurement Input						2.8	2.8
Warrant [Member] | Measurement Input, Expected Term [Member] | Series B Warrants [Member]
Warrants and Rights Outstanding, Measurement Input			3.9	3.9
Warrant [Member] | Measurement Input, Expected Term [Member] | Series A-2 and Series B-2 Warrants [Member]
Warrants and Rights Outstanding, Measurement Input			4.3	4.3
Warrant [Member] | Measurement Input, Expected Term [Member] | Series B, A-2 and B-2 Warrants [Member]
Warrants and Rights Outstanding, Measurement Input	3.6	3.6
Warrant [Member] | Measurement Input, Price Volatility [Member]
Warrants and Rights Outstanding, Measurement Input						0.97	0.97
Warrant [Member] | Measurement Input, Price Volatility [Member] | Series B Warrants [Member]
Warrants and Rights Outstanding, Measurement Input			0.90	0.90
Warrant [Member] | Measurement Input, Price Volatility [Member] | Series A-2 and Series B-2 Warrants [Member]
Warrants and Rights Outstanding, Measurement Input			0.90	0.90
Warrant [Member] | Measurement Input, Price Volatility [Member] | Series B, A-2 and B-2 Warrants [Member]
Warrants and Rights Outstanding, Measurement Input	0.80	0.80
Warrant [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrants and Rights Outstanding, Measurement Input						0.0027	0.0027
Warrant [Member] | Measurement Input, Risk Free Interest Rate [Member] | Series B Warrants [Member]
Warrants and Rights Outstanding, Measurement Input			0.0033	0.0033
Warrant [Member] | Measurement Input, Risk Free Interest Rate [Member] | Series A-2 and Series B-2 Warrants [Member]
Warrants and Rights Outstanding, Measurement Input			0.0033	0.0033
Warrant [Member] | Measurement Input, Risk Free Interest Rate [Member] | Series B, A-2 and B-2 Warrants [Member]
Warrants and Rights Outstanding, Measurement Input	0.0058	0.0058
Warrant [Member] | Measurement Input, Expected Dividend Rate [Member]
Warrants and Rights Outstanding, Measurement Input						0	0
Warrant [Member] | Measurement Input, Expected Dividend Rate [Member] | Series B Warrants [Member]
Warrants and Rights Outstanding, Measurement Input			0	0
Warrant [Member] | Measurement Input, Expected Dividend Rate [Member] | Series A-2 and Series B-2 Warrants [Member]
Warrants and Rights Outstanding, Measurement Input			0	0
Warrant [Member] | Measurement Input, Expected Dividend Rate [Member] | Series B, A-2 and B-2 Warrants [Member]
Warrants and Rights Outstanding, Measurement Input	0	0

Note 13 - Summary of Stock Op_3

Note 13 - Summary of Stock Options (Details Textual) - USD ($)	Aug. 22, 2016	Jan. 31, 2021	Jan. 31, 2020	Aug. 31, 2017	Dec. 31, 2021	Sep. 30, 2021	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2021	Dec. 31, 2020	Jun. 30, 2021	May 31, 2021	Sep. 30, 2020	Jan. 01, 2020
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance (in shares)					3,173,103				3,173,103	986,399
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance (in dollars per share)					$ 7.51				$ 7.51	$ 19.10
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term (Year)									9 years	8 years 10 months 24 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)									2,251,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in shares)									0
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate									0.00%	0.00%
Restricted Stock Units (RSUs) [Member]
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total					$ 1,151,000				$ 1,151,000
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)									1 year 1 month 6 days
Share-based Payment Arrangement, Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate									0.00%
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total					$ 5,831,000				$ 5,831,000
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)									2 years 9 months 18 days
The 2006 Stock Option Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance (in shares)					12				12
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares)					0				0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance (in dollars per share)					$ 9,920				$ 9,920
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term (Year)									1 year 1 month 6 days
The 2013 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance (in shares)					3,173,091				3,173,091
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares)					94,392				94,392
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance (in dollars per share)					$ 7.48				$ 7.48
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term (Year)									9 years
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)									10 years
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)									4 years
Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum									10.00%
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent									110.00%
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized, Percentage Increase of Outstanding Common Stock	4.00%
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized (in shares)		307,705	263,993
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)		1,758,951			3,940,136				3,940,136	1,451,246	3,940,136			1,451,246
The 2013 Plan [Member] | Employees and Nonemployees [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)									2,251,000	146,700
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)									$ 1.75	$ 4.08
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in shares)									0	0
The 2013 Plan [Member] | Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Ending Balance (in shares)					674,000				674,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)									0
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period (in shares)									16,000
The 2013 Plan [Member] | Restricted Stock Units (RSUs) [Member] | Employees and Board Members [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)		690,000
The 2013 Plan [Member] | Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Ending Balance (in shares)					228				228
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)									0	0
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period (in shares)									6	18
The 2013 Plan [Member] | Holdings Greater Than 10 Percent of Shares Outstanding [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)									5 years
2017 Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent				85.00%
Share-based Compensation Arrangement by Share-based Payment Award, Maximum Number of Shares Per Employee (in shares)				200
Stock Issued During Period, Shares, Employee Stock Purchase Plans (in shares)					17,286	10,844	30	32
Shares Issued, Price Per Share (in dollars per share)					$ 0.97	$ 1.94	$ 4.79	$ 5.86	$ 0.97				$ 4.44
Employee Stock Ownership Plan (ESOP), Number of Suspense Shares (in shares)					471,870				471,870				22
Common Stock, Capital Shares Reserved for Future Issuance (in shares)											500,378	400
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant During Offering Period (in shares)											2,000	2

Note 13 - Summary of Stock Op_4

Note 13 - Summary of Stock Options - Summary of Option Activity Under All Plans (Details) - USD ($)	1 Months Ended	12 Months Ended
	Jan. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Options outstanding (in shares)	3,173,103	986,399
Options outstanding, weighted average exercise price (in dollars per share)	$ 7.51	$ 19.10
Options outstanding, weighted average remaining contractual term (Year)		9 years	8 years 10 months 24 days
Options outstanding, aggregate intrinsic value		$ 0	$ 675,000
Options granted (in shares)		2,251,000
Options granted, weighted average exercise price (in dollars per share)		$ 2.73
Options exercised (in shares)		0
Options exercised, weighted average exercise price (in dollars per share)
Options canceled (in shares)		(64,296)
Options canceled, weighted average exercise price (in dollars per share)		$ 17.85
Vested and exercisable and expected to vest (in shares)		2,947,472
Vested and exercisable and expected to vest, end of period, weighted average exercise price (in dollars per share)		$ 7.83
Vested and exercisable and expected to vest, end of period, weighted average remaining contractual term (Year)		9 years
Vested and exercisable and expected to vest, end of period, aggregate intrinsic value		$ 0
Vested and exercisable (in shares)		774,800
Vested and exercisable, end of period, weighted average exercise price (in dollars per share)		$ 18.81
Vested and exercisable, end of period, weighted average remaining contractual term (Year)		8 years 6 months
Vested and exercisable, end of period, aggregate intrinsic value		$ 0

Note 13 - Summary of Stock Op_5

Note 13 - Summary of Stock Options - Summary of Options Outstanding and Exercisable (Details)	12 Months Ended
	Dec. 31, 2021$ / sharesshares
Options outstanding, number (in shares) | shares	3,173,103
Options outstanding, weighted average exercise price (in dollars per share)	$ 7.51
Options outstanding, weighted average remaining contractual term (Year)	9 years
Options exercisable, number exercisable (in shares) | shares	774,800
Options exercisable, weighted average exercise price (in dollars per share)	$ 18.81
Range One [Member]
Exercise price range, lower limit (in dollars per share)	2.28
Exercise price range, upper limit (in dollars per share)	$ 2.96
Options outstanding, number (in shares) | shares	2,208,063
Options outstanding, weighted average exercise price (in dollars per share)	$ 2.73
Options outstanding, weighted average remaining contractual term (Year)	9 years 6 months
Options exercisable, number exercisable (in shares) | shares	259,301
Options exercisable, weighted average exercise price (in dollars per share)	$ 2.73
Range Two [Member]
Exercise price range, lower limit (in dollars per share)	3.06
Exercise price range, upper limit (in dollars per share)	$ 3.40
Options outstanding, number (in shares) | shares	10,000
Options outstanding, weighted average exercise price (in dollars per share)	$ 3.20
Options outstanding, weighted average remaining contractual term (Year)	9 years 2 months 12 days
Options exercisable, number exercisable (in shares) | shares	0
Options exercisable, weighted average exercise price (in dollars per share)	$ 0
Range Three [Member]
Exercise price range, lower limit (in dollars per share)	4.45
Exercise price range, upper limit (in dollars per share)	$ 4.80
Options outstanding, number (in shares) | shares	11,900
Options outstanding, weighted average exercise price (in dollars per share)	$ 4.72
Options outstanding, weighted average remaining contractual term (Year)	8 years 10 months 24 days
Options exercisable, number exercisable (in shares) | shares	3,088
Options exercisable, weighted average exercise price (in dollars per share)	$ 4.71
Range Four [Member]
Exercise price range, lower limit (in dollars per share)	5.10
Exercise price range, upper limit (in dollars per share)	$ 5.40
Options outstanding, number (in shares) | shares	88,000
Options outstanding, weighted average exercise price (in dollars per share)	$ 5.28
Options outstanding, weighted average remaining contractual term (Year)	8 years 9 months 18 days
Options exercisable, number exercisable (in shares) | shares	62,219
Options exercisable, weighted average exercise price (in dollars per share)	$ 5.34
Range Five [Member]
Exercise price range, lower limit (in dollars per share)	6.90
Exercise price range, upper limit (in dollars per share)	$ 6.90
Options outstanding, number (in shares) | shares	5,400
Options outstanding, weighted average exercise price (in dollars per share)	$ 6.90
Options outstanding, weighted average remaining contractual term (Year)	8 years 3 months 18 days
Options exercisable, number exercisable (in shares) | shares	2,364
Options exercisable, weighted average exercise price (in dollars per share)	$ 6.90
Range Six [Member]
Exercise price range, lower limit (in dollars per share)	8.60
Exercise price range, upper limit (in dollars per share)	$ 8.91
Options outstanding, number (in shares) | shares	830,825
Options outstanding, weighted average exercise price (in dollars per share)	$ 8.69
Options outstanding, weighted average remaining contractual term (Year)	7 years 10 months 24 days
Options exercisable, number exercisable (in shares) | shares	433,263
Options exercisable, weighted average exercise price (in dollars per share)	$ 8.69
Range Seven [Member]
Exercise price range, lower limit (in dollars per share)	10.90
Exercise price range, upper limit (in dollars per share)	$ 13.60
Options outstanding, number (in shares) | shares	15,500
Options outstanding, weighted average exercise price (in dollars per share)	$ 12.64
Options outstanding, weighted average remaining contractual term (Year)	8 years 2 months 12 days
Options exercisable, number exercisable (in shares) | shares	11,271
Options exercisable, weighted average exercise price (in dollars per share)	$ 13
Range Eight [Member]
Exercise price range, lower limit (in dollars per share)	380
Exercise price range, upper limit (in dollars per share)	$ 9,920
Options outstanding, number (in shares) | shares	3,415
Options outstanding, weighted average exercise price (in dollars per share)	$ 2,873.63
Options outstanding, weighted average remaining contractual term (Year)	6 years 2 months 12 days
Options exercisable, number exercisable (in shares) | shares	3,294
Options exercisable, weighted average exercise price (in dollars per share)	$ 2,911.12

Note 13 - Summary of Stock Op_6

Note 13 - Summary of Stock Options - Valuation Assumptions for Stock Options (Details)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Expected term (Year)	6 years	5 years
Average volatility	76.00%	82.00%
Risk-free interest rate	0.97%	0.37%
Dividend yield	0.00%	0.00%

Note 13 - Summary of Stock Op_7

Note 13 - Summary of Stock Options - Stock-based Compensation Expense Included in the Statement of Income (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Stock-based compensation expense	$ 3,779	$ 2,651
Cost of Sales [Member]
Stock-based compensation expense	265	208
Research and Development Expense [Member]
Stock-based compensation expense	456	325
Selling, General and Administrative Expenses [Member]
Stock-based compensation expense	$ 3,058	$ 2,118

Note 14 - Income Taxes (Details

Note 14 - Income Taxes (Details Textual) - USD ($) Pure in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Income Tax Expense (Benefit), Total	$ 0
Effective Income Tax Rate Reconciliation, Percent, Total	0.00%	0.00%
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount	$ 4,593,000	$ (4,352,000)
Deferred Tax Assets, Tax Credit Carryforwards, Research	781,000	631,000
Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Total	0
Unrecognized Tax Benefits, Ending Balance	231,000	$ 245,000	$ 223,000
Unrecognized Tax Benefits that Would Impact Effective Tax Rate	0
Domestic Tax Authority [Member]
Operating Loss Carryforwards, Total	112,951,000
State and Local Jurisdiction [Member]
Operating Loss Carryforwards, Total	34,469,000
State and Local Jurisdiction [Member] | California Franchise Tax Board [Member]
Deferred Tax Assets, Tax Credit Carryforwards, Research	768,000
State and Local Jurisdiction [Member] | Colorado Department Of Revenue [Member] | Job Growth Incentive Tax Credits [Member]
Deferred Tax Assets, Tax Credit Carryforwards, Total	$ 451,000

Note 14 - Income Taxes - Provis

Note 14 - Income Taxes - Provision for Income Taxes Computed at Federal Statutory Rate (Details)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Income tax benefit at statutory rate	(21.00%)	(21.00%)
State income taxes, net of federal benefit	(3.00%)	(3.00%)
Change in valuation allowance	21.00%	20.00%
Other	3.00%	4.00%
Effective tax rate	0.00%	0.00%

Note 14 - Income Taxes - Signif

Note 14 - Income Taxes - Significant Components of Deferred Tax Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Net operating loss carryforwards	$ 25,092	$ 20,891
Capitalized start up costs	2,511	2,866
Research and development credits	781	631
Accruals and reserves	1,537	773
Fixed assets and depreciation	(124)	(291)
Total deferred tax assets	30,045	25,452
Valuation allowance	(30,045)	(25,452)
Net deferred tax assets	$ 0	$ 0

Note 14 - Income Taxes - Unreco

Note 14 - Income Taxes - Unrecognized Tax Benefit Roll Forward (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Balance	$ 245,000	$ 223,000
Additions (deletions) based upon tax positions related to the current year	(14,000)	22,000
Balance	$ 231,000	$ 245,000

Note 15 - Related Party Trans_2

Note 15 - Related Party Transactions (Details Textual) - Stellartech Research Corporation [Member]	1 Months Ended	12 Months Ended
	Jun. 30, 2006	Dec. 31, 2021USD ($)shares	Dec. 31, 2020USD ($)
Stock Issued During Period, Shares, New Issues (in shares) | shares		38
Related Party Transaction, Amounts of Transaction | $		$ 205,000	$ 1,051,000
Electricity, Generation [Member]
Development and Manufacturing Agreement, Number of Units	300
Development and Manufacturing Agreement, Number of Units Purchased	855

Note 16 - Segments and Geogra_3

Note 16 - Segments and Geographic Information - Segments and Geographic Information (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Long-lived assets	$ 1,554	$ 2,759
UNITED STATES
Long-lived assets	1,553	2,622
Asia Pacific [Member]
Long-lived assets	0	76
CANADA
Long-lived assets	1	54
Europe [Member]
Long-lived assets	$ 0	$ 7

Note 17 - Subsequent Events (De

Note 17 - Subsequent Events (Details Textual)	Jan. 18, 2022USD ($)	Jan. 01, 2022shares	Jan. 31, 2022$ / sharesshares	Jan. 31, 2021shares	Jan. 31, 2020shares	Dec. 31, 2021shares	Mar. 14, 2022shares	Jun. 30, 2021shares	Mar. 31, 2021shares	Dec. 31, 2020shares	Jan. 01, 2020shares
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)						2,251,000
Series C Preferred Stock [Member]
Preferred Stock, Shares Outstanding, Ending Balance (in shares)				0		0			0	0
Preferred Stock, Shares Authorized (in shares)						10,000,000				10,000,000
Subsequent Event [Member] | Series C Preferred Stock [Member]
Preferred Stock, Shares Outstanding, Ending Balance (in shares)							0
Preferred Stock, Shares Authorized (in shares)							2,450,880
Subsequent Event [Member] | Deferred Bonus [Member]
Retention Bonus to Certain Key Employees | $	$ 700,000
Retention Bonus to Certain Key Employees, Number of Installments	2
The 2013 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized (in shares)				307,705	263,993
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)				1,758,951		3,940,136		3,940,136		1,451,246	1,451,246
The 2013 Plan [Member] | Subsequent Event [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized (in shares)		1,076,833
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)		5,016,969
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)			941,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share) | $ / shares			$ 1.26
Share-Based Compensation Arrangement by Share-Based Payment Award, Vested and Expected to Vest, Number of Installments			48